Master Alliance Provisions Guide (MAPGuide)

All Agreements

(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
Agreement
AbbVie - MPP, HIV Antiretroviral License Agreement
2016
Industry
Multilateral organization
Drug
Commercialization
Array
(
    [ip-ownership.license-grants.mpps-license-agreement-with-abbvie] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 1118
            [provision_permalink] => https://ghiaa.org/provision_document/mpps-license-agreement-with-abbvie/
            [children] => 
        )

)
AbbVie - MPP, HIV Antiretroviral Sublicense Agreement
2014
Industry
Multilateral organization
Drug
Commercialization
Array
(
    [access-to-medicines.territory-access-commitments.mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 1125
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-2/
            [children] => 
        )

    [ip-ownership.license-grants.mpp-license-agreement-with-abbvie] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 1183
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-abbvie/
            [children] => 
        )

    [liability.indemnity.mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1313
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-3/
            [children] => 
        )

)
Academic Institution - Company, Research Collaboration Agreement
2016
Academic institution
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [access-to-medicines.equitable-access.redacted-collaboration-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 1220
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-2/
            [children] => 
        )

    [business-model.roles-responsibilities.academic-institution-company-research-collaboration-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4090
            [provision_permalink] => https://ghiaa.org/provision_document/academic-institution-company-research-collaboration-agreement/
            [children] => 
        )

    [information-sharing.confidentiality.redacted-collaboration-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 1248
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-6/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.redacted-collaboration-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 1233
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-4/
            [children] => 
        )

    [information-sharing.publication-of-results.redacted-collaboration-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 1233
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-4/
            [children] => 
        )

    [information-sharing.technology-transfer.redacted-collaboration-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 1238
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-5/
            [children] => 
        )

    [ip-ownership.license-grants.academic-institution-company-research-collaboration-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 4092
            [provision_permalink] => https://ghiaa.org/provision_document/academic-institution-company-research-collaboration-agreement-3/
            [children] => 
        )

    [ip-ownership.ownership-ip.redacted-collaboration-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 1150
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement/
            [children] => 
        )

    [ip-ownership.protection-results.academic-institution-company-research-collaboration-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 4093
            [provision_permalink] => https://ghiaa.org/provision_document/academic-institution-company-research-collaboration-agreement-4/
            [children] => 
        )

    [liability.indemnity.academic-institution-company-research-collaboration-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 4095
            [provision_permalink] => https://ghiaa.org/provision_document/academic-institution-company-research-collaboration-agreement-6/
            [children] => 
        )

    [liability.insurance.academic-institution-company-research-collaboration-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 4098
            [provision_permalink] => https://ghiaa.org/provision_document/academic-institution-company-research-collaboration-agreement-9/
            [children] => 
        )

    [liability.warranties.academic-institution-company-research-collaboration-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4094
            [provision_permalink] => https://ghiaa.org/provision_document/academic-institution-company-research-collaboration-agreement-5/
            [children] => 
        )

    [term-and-termination.effect-of-termination.redacted-collaboration-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 1282
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-7/
            [children] => 
        )

    [term-and-termination.term-of-agreement.redacted-collaboration-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 1282
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-7/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.redacted-collaboration-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 1282
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-7/
            [children] => 
        )

)
Alnylam Pharmaceuticals - University of British Columbia- AlCana Technology, Sponsored Research Agreement
2009
Academic institution
Industry
Drug
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 5688
            [provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-5/
            [children] => 
        )

    [access-to-medicines.equitable-access.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 5684
            [provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-4/
            [children] => 
        )

    [business-model.roles-responsibilities.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 5694
            [provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-11/
            [children] => 
        )

    [business-model.royalties-and-payments.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 5693
            [provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-10/
            [children] => 
        )

    [information-sharing.confidentiality.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 5689
            [provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-6/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 5691
            [provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-8/
            [children] => 
        )

    [information-sharing.publication-of-results.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 5690
            [provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-7/
            [children] => 
        )

    [information-sharing.technology-transfer.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 5692
            [provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-9/
            [children] => 
        )

    [ip-ownership.license-grants.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 5682
            [provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-2/
            [children] => 
        )

    [ip-ownership.ownership-ip.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 5681
            [provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement/
            [children] => 
        )

    [ip-ownership.protection-results.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 5683
            [provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-3/
            [children] => 
        )

    [liability.indemnity.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 5695
            [provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-12/
            [children] => 
        )

    [liability.insurance.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 5696
            [provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-13/
            [children] => 
        )

    [liability.warranties.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 5697
            [provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-14/
            [children] => 
        )

    [term-and-termination.effect-of-termination.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 5700
            [provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-17/
            [children] => 
        )

    [term-and-termination.term-of-agreement.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 5698
            [provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-15/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 5699
            [provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-16/
            [children] => 
        )

)
AUTM Model Inter-Institutional Research Collaboration Agreement
2015
Academic institution
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [business-model.benefit-revenue-sharing.autm-model-inter-institutional-research-collaboration-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 66
            [slug] => benefit-revenue-sharing
            [title] => Benefit sharing
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Benefit sharing
            [provision_id] => 4105
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-inter-institutional-research-collaboration-agreement/
            [children] => 
        )

    [business-model.royalties-and-payments.autm-model-inter-institutional-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3698
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-inter-institutional-agreement/
            [children] => 
        )

    [information-sharing.confidentiality.autm-model-iia-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 1243
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-5/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.autm-model-inter-institutional-research-collaboration-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4113
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-inter-institutional-research-collaboration-agreement-3/
            [children] => 
        )

    [ip-ownership.license-grants.autm-model-iia-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 1182
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-3/
            [children] => 
        )

    [ip-ownership.protection-results.autm-model-iia] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 1164
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia/
            [children] => 
        )

    [liability.indemnity.autm-model-iia-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1273
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-6/
            [children] => 
        )

    [liability.warranties.lambert-agreement-d-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 1259
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-9/
            [children] => 
        )

    [term-and-termination.effect-of-termination.autm-model-inter-institutional-research-collaboration-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4112
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-inter-institutional-research-collaboration-agreement-2/
            [children] => 
        )

    [term-and-termination.term-of-agreement.autm-model-iia-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 1280
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-7/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.autm-model-iia-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 1280
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-7/
            [children] => 
        )

)
AUTM Preliminary Patent Management Agreement
2013
Academic institution
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [business-model.royalties-and-payments.autm-preliminary-patent-management-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 8458
            [provision_permalink] => https://ghiaa.org/provision_document/autm-preliminary-patent-management-agreement-3/
            [children] => 
        )

    [ip-ownership.license-grants.autm-preliminary-patent-management-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 8457
            [provision_permalink] => https://ghiaa.org/provision_document/autm-preliminary-patent-management-agreement-2/
            [children] => 
        )

    [ip-ownership.protection-results.autm-preliminary-patent-management-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 8456
            [provision_permalink] => https://ghiaa.org/provision_document/autm-preliminary-patent-management-agreement/
            [children] => 
        )

    [liability.indemnity.autm-preliminary-patent-management-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 8460
            [provision_permalink] => https://ghiaa.org/provision_document/autm-preliminary-patent-management-agreement-5/
            [children] => 
        )

    [term-and-termination.term-of-agreement.autm-preliminary-patent-management-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 8459
            [provision_permalink] => https://ghiaa.org/provision_document/autm-preliminary-patent-management-agreement-4/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.autm-preliminary-patent-management-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 8459
            [provision_permalink] => https://ghiaa.org/provision_document/autm-preliminary-patent-management-agreement-4/
            [children] => 
        )

)
AXA Prime Impact Master Fund - Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
2020
Funder
Industry
Diagnostic
Drug
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 5775
            [provision_permalink] => https://ghiaa.org/provision_document/axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement/
            [children] => 
        )

    [access-to-medicines.equitable-access.axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 5776
            [provision_permalink] => https://ghiaa.org/provision_document/axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-2/
            [children] => 
        )

    [access-to-medicines.pricing.axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 5777
            [provision_permalink] => https://ghiaa.org/provision_document/axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-3/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 5778
            [provision_permalink] => https://ghiaa.org/provision_document/axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-4/
            [children] => 
        )

    [business-model.supply-purchase-of-products.axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 5778
            [provision_permalink] => https://ghiaa.org/provision_document/axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 5779
            [provision_permalink] => https://ghiaa.org/provision_document/axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-5/
            [children] => 
        )

    [ip-ownership.license-grants.axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 5775
            [provision_permalink] => https://ghiaa.org/provision_document/axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement/
            [children] => 
        )

    [term-and-termination.term-of-agreement.axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 5781
            [provision_permalink] => https://ghiaa.org/provision_document/axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-6/
            [children] => 
        )

)
BARDA - Moderna, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Array
(
    [access-to-medicines.ensuring-continuity.barda-moderna-covid-19-vaccine-development-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 3758
            [provision_permalink] => https://ghiaa.org/provision_document/barda-moderna-covid-19-vaccine-development-agreement-2/
            [children] => 
        )

    [business-model.roles-responsibilities.moderna-barda-contract-for-development-of-mrna-vaccine-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 2444
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-5/
            [children] => 
        )

    [information-sharing.confidentiality.moderna-barda-contract-for-development-of-mrna-vaccine-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 2443
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.barda-moderna-covid-19-vaccine-development-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3764
            [provision_permalink] => https://ghiaa.org/provision_document/barda-moderna-covid-19-vaccine-development-agreement-3/
            [children] => 
        )

    [ip-ownership.license-grants.moderna-barda-contract-for-development-of-mrna-vaccine-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 2442
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-3/
            [children] => 
        )

    [ip-ownership.ownership-ip.moderna-barda-contract-for-development-of-mrna-vaccine-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 2442
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-3/
            [children] => 
        )

    [ip-ownership.protection-results.moderna-barda-contract-for-development-of-mrna-vaccine-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 2442
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-3/
            [children] => 
        )

    [liability.indemnity.moderna-barda-contract-for-development-of-mrna-vaccine-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 2441
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-2/
            [children] => 
        )

)
Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.pricing.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 4214
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3/
            [children] => 
        )

    [business-model.regulatory-strategy.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 4223
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14/
            [children] => 
        )

    [business-model.roles-responsibilities.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4222
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13/
            [children] => 
        )

    [business-model.royalties-and-payments.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 4214
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3/
            [children] => 
        )

    [business-model.supply-purchase-of-products.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 4213
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5/
            [children] => 
        )

    [information-sharing.confidentiality.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4212
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4221
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12/
            [children] => 
        )

    [ip-ownership.license-grants.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 4209
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement/
            [children] => 
        )

    [ip-ownership.ownership-ip.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 4209
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement/
            [children] => 
        )

    [ip-ownership.protection-results.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 4210
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2/
            [children] => 
        )

    [liability.indemnity.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 4215
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6/
            [children] => 
        )

    [liability.insurance.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 4216
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7/
            [children] => 
        )

    [liability.warranties.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4217
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8/
            [children] => 
        )

    [term-and-termination.effect-of-termination.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4220
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11/
            [children] => 
        )

    [term-and-termination.term-of-agreement.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 4218
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 4219
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10/
            [children] => 
        )

)
BMS - MPP - Aurobindo, Daclatasvir Sublicense & Tech Transfer Agreement
2016
Industry
Multilateral organization
Drug
Commercialization
Array
(
    [access-to-medicines.pricing.mpp-license-agreement-with-bms-aurobindo-pharma-ltd] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 1122
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-bms-aurobindo-pharma-ltd/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.mpp-license-agreement-with-bms-aurobindo-pharma-ltd] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 1122
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-bms-aurobindo-pharma-ltd/
            [children] => 
        )

    [information-sharing.technology-transfer.mpp-license-agreement-with-bms-aurobindo-pharma-ltd-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 1229
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-bms-aurobindo-pharma-ltd-2/
            [children] => 
        )

)
BMS - MPP Sublicense & Tech Transfer Agreement
2017
Industry
Multilateral organization
Drug
Commercialization
Array
(
    [business-model.regulatory-strategy.mpp-bms-sublicense-tech-transfer-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 3914
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-bms-sublicense-tech-transfer-agreement/
            [children] => 
        )

    [ip-ownership.license-grants.mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 1124
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement/
            [children] => 
        )

    [liability.indemnity.mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1314
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2/
            [children] => 
        )

    [liability.insurance.mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 1314
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2/
            [children] => 
        )

    [term-and-termination.term-of-agreement.mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 1124
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement/
            [children] => 
        )

)
Boston University Startup Exclusive License Template
2012
Academic institution
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [access-to-medicines.equitable-access.boston-university-startup-exclusive-license-template] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 4858
            [provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.boston-university-startup-exclusive-license-template-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 4863
            [provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template-6/
            [children] => 
        )

    [business-model.roles-responsibilities.boston-university-startup-exclusive-license-template-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4868
            [provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template-11/
            [children] => 
        )

    [business-model.royalties-and-payments.boston-university-startup-exclusive-license-template-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 4864
            [provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template-7/
            [children] => 
        )

    [information-sharing.confidentiality.boston-university-startup-exclusive-license-template-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4869
            [provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template-12/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.boston-university-startup-exclusive-license-template-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4861
            [provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template-4/
            [children] => 
        )

    [ip-ownership.license-grants.bu-startup-exclusive-license] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 1127
            [provision_permalink] => https://ghiaa.org/provision_document/bu-startup-exclusive-license/
            [children] => 
        )

    [ip-ownership.protection-results.boston-university-startup-exclusive-license-template-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 4859
            [provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template-2/
            [children] => 
        )

    [liability.indemnity.bu-startup-exclusive-license-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1272
            [provision_permalink] => https://ghiaa.org/provision_document/bu-startup-exclusive-license-2/
            [children] => 
        )

    [liability.insurance.boston-university-startup-exclusive-license-template-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 4865
            [provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template-8/
            [children] => 
        )

    [liability.warranties.boston-university-startup-exclusive-license-template-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4860
            [provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template-3/
            [children] => 
        )

    [term-and-termination.effect-of-termination.boston-university-startup-exclusive-license-template-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4867
            [provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template-10/
            [children] => 
        )

    [term-and-termination.term-of-agreement.boston-university-startup-exclusive-license-template-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 4866
            [provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template-9/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.boston-university-startup-exclusive-license-template-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 4862
            [provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template-5/
            [children] => 
        )

)
CARB-X Portfolio Company Agreement Template
2019
Academic institution
Funder
Industry
Product development partnership
Diagnostic
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Array
(
    [access-to-medicines.ensuring-continuity.carb-x-research-subaward-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 1187
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-2/
            [children] => 
        )

    [access-to-medicines.equitable-access.carb-x-research-subaward-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 4516
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.carb-x-research-subaward-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 5622
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-4/
            [children] => 
        )

    [business-model.regulatory-strategy.carb-x-research-subaward-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 5625
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-14/
            [children] => 
        )

    [business-model.roles-responsibilities.carb-x-research-subaward-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 5624
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-6/
            [children] => 
        )

    [business-model.royalties-and-payments.carb-x-research-subaward-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 5626
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-7/
            [children] => 
        )

    [information-sharing.confidentiality.carb-x-research-subaward-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 5627
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-8/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.carb-x-research-subaward-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 5623
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-5/
            [children] => 
        )

    [information-sharing.publication-of-results.carb-x-research-subaward-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 1218
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-3/
            [children] => 
        )

    [ip-ownership.ownership-ip.carb-x-research-subaward-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 5632
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-11/
            [children] => 
        )

    [liability.indemnity.carb-x-research-subaward-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 5633
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-12/
            [children] => 
        )

    [liability.insurance.carb-x-research-subaward-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 5634
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-13/
            [children] => 
        )

    [liability.warranties.carb-x-research-subaward-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 5631
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-10/
            [children] => 
        )

    [term-and-termination.effect-of-termination.carb-x-research-subaward-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 5629
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-9/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.carb-x-research-subaward-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 5629
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-9/
            [children] => 
        )

)
CAVD Data & Materials Sharing Agreement
2006
Academic institution
Funder
Government
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [information-sharing.confidentiality.gates-foundation-data-materials-sharing-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 1254
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-data-materials-sharing-agreement-4/
            [children] => 
        )

    [ip-ownership.license-grants.cavd-data-materials-sharing-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 1134
            [provision_permalink] => https://ghiaa.org/provision_document/cavd-data-materials-sharing-agreement-2/
            [children] => 
        )

    [ip-ownership.ownership-ip.cavd-data-materials-sharing-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 1134
            [provision_permalink] => https://ghiaa.org/provision_document/cavd-data-materials-sharing-agreement-2/
            [children] => 
        )

)
Cellscript - BioNTech mRNA Technology Patent Sublicense
2016
Industry
Vaccine
Preclinical
Array
(
    [business-model.roles-responsibilities.cellscript-biontech-mrna-technology-patent-sublicense-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4490
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-11/
            [children] => 
        )

    [business-model.royalties-and-payments.cellscript-biontech-mrna-technology-patent-sublicense-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 4483
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-4/
            [children] => 
        )

    [information-sharing.confidentiality.cellscript-biontech-mrna-technology-patent-sublicense-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4482
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-3/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.cellscript-biontech-mrna-technology-patent-sublicense-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4489
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-10/
            [children] => 
        )

    [ip-ownership.license-grants.cellscript-biontech-mrna-technology-patent-sublicense] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 4469
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense/
            [children] => 
        )

    [ip-ownership.protection-results.cellscript-biontech-mrna-technology-patent-sublicense-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 4481
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-2/
            [children] => 
        )

    [liability.indemnity.cellscript-biontech-mrna-technology-patent-sublicense-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 4484
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-5/
            [children] => 
        )

    [liability.insurance.cellscript-biontech-mrna-technology-patent-sublicense-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 4491
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-12/
            [children] => 
        )

    [liability.warranties.cellscript-biontech-mrna-technology-patent-sublicense-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4485
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-6/
            [children] => 
        )

    [term-and-termination.effect-of-termination.cellscript-biontech-mrna-technology-patent-sublicense-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4488
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-9/
            [children] => 
        )

    [term-and-termination.term-of-agreement.cellscript-biontech-mrna-technology-patent-sublicense-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 4486
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-7/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.cellscript-biontech-mrna-technology-patent-sublicense-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 4487
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-8/
            [children] => 
        )

)
CEPI - CureVac, Framework Partnering Agreement
2019
Funder
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.cepi-curevac-framework-partnering-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 3329
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-11/
            [children] => 
        )

    [access-to-medicines.equitable-access.cepi-curevac-framework-partnering-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 8461
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-7/
            [children] => 
        )

    [access-to-medicines.outbreak-preparedness.cepi-curevac-framework-partnering-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 102
            [slug] => outbreak-preparedness
            [title] => Preparedness & response
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Preparedness & response
            [provision_id] => 3327
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-9/
            [children] => 
        )

    [access-to-medicines.pricing.cepi-curevac-framework-partnering-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 5427
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-5/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.cepi-curevac-framework-partnering-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 4580
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-3/
            [children] => 
        )

    [business-model.benefit-revenue-sharing.cepi-curevac-framework-partnering-agreement-13-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 66
            [slug] => benefit-revenue-sharing
            [title] => Benefit sharing
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Benefit sharing
            [provision_id] => 3321
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-13-2/
            [children] => 
        )

    [business-model.regulatory-strategy.cepi-curevac-framework-partnering-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 3318
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-4/
            [children] => 
        )

    [business-model.roles-responsibilities.cepi-curevac-framework-partnering-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 3323
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-6/
            [children] => 
        )

    [business-model.royalties-and-payments.cepi-curevac-framework-partnering-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3315
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement/
            [children] => 
        )

    [information-sharing.confidentiality.cepi-curevac-framework-partnering-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3338
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-16/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.cepi-curevac-framework-partnering-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3316
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-2/
            [children] => 
        )

    [information-sharing.publication-of-results.cepi-curevac-framework-partnering-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 3326
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-8/
            [children] => 
        )

    [information-sharing.technology-transfer.cepi-curevac-framework-partnering-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 4580
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-3/
            [children] => 
        )

    [ip-ownership.license-grants.cepi-curevac-framework-partnering-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 3329
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-11/
            [children] => 
        )

    [ip-ownership.ownership-ip.cepi-curevac-framework-partnering-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 3331
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-13/
            [children] => 
        )

    [ip-ownership.protection-results.cepi-curevac-framework-partnering-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 3336
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-14/
            [children] => 
        )

    [liability.indemnity.cepi-curevac-framework-partnering-agreement-19] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3341
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-19/
            [children] => 
        )

    [liability.insurance.cepi-curevac-framework-partnering-agreement-20] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 3342
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-20/
            [children] => 
        )

    [liability.warranties.cepi-curevac-framework-partnering-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3339
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-17/
            [children] => 
        )

    [term-and-termination.effect-of-termination.cepi-curevac-framework-partnering-agreement-22] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 3344
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-22/
            [children] => 
        )

    [term-and-termination.term-of-agreement.cepi-curevac-framework-partnering-agreement-21] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3343
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-21/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.cepi-curevac-framework-partnering-agreement-21] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 3343
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-21/
            [children] => 
        )

)
CEPI - Dynavax, COVID-19 Material Reservation Agreement
2021
Funder
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.equitable-access.cepi-dynavax-covid-19-material-reservation-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 4128
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement/
            [children] => 
        )

    [access-to-medicines.pricing.cepi-dynavax-covid-19-material-reservation-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 4129
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-2/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.cepi-dynavax-covid-19-material-reservation-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 4129
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-2/
            [children] => 
        )

    [business-model.regulatory-strategy.cepi-dynavax-covid-19-material-reservation-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 4141
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-13/
            [children] => 
        )

    [business-model.roles-responsibilities.cepi-dynavax-covid-19-material-reservation-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4140
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-12/
            [children] => 
        )

    [business-model.royalties-and-payments.cepi-dynavax-covid-19-material-reservation-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 4133
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-5/
            [children] => 
        )

    [business-model.supply-purchase-of-products.cepi-dynavax-covid-19-material-reservation-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 4131
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-4/
            [children] => 
        )

    [information-sharing.confidentiality.cepi-dynavax-covid-19-material-reservation-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4130
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-3/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.cepi-dynavax-covid-19-material-reservation-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4139
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-11/
            [children] => 
        )

    [liability.indemnity.cepi-dynavax-covid-19-material-reservation-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 4134
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-6/
            [children] => 
        )

    [liability.warranties.cepi-dynavax-covid-19-material-reservation-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4135
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-7/
            [children] => 
        )

    [term-and-termination.effect-of-termination.cepi-dynavax-covid-19-material-reservation-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4138
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-10/
            [children] => 
        )

    [term-and-termination.term-of-agreement.cepi-dynavax-covid-19-material-reservation-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 4136
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-8/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.cepi-dynavax-covid-19-material-reservation-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 4137
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-9/
            [children] => 
        )

)
CEPI - Novavax, COVID-19 Vaccine Funding Agreement
2020
Funder
Industry
Vaccine
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 2890
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5/
            [children] => 
        )

    [access-to-medicines.equitable-access.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 2892
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6/
            [children] => 
        )

    [access-to-medicines.outbreak-preparedness.cepi-novavax-covid-19-vaccine-funding-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 102
            [slug] => outbreak-preparedness
            [title] => Preparedness & response
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Preparedness & response
            [provision_id] => 5782
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-novavax-covid-19-vaccine-funding-agreement-8/
            [children] => 
        )

    [access-to-medicines.pricing.cepi-novavax-covid-19-vaccine-funding-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 5652
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-novavax-covid-19-vaccine-funding-agreement-6/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.cepi-novavax-covid-19-vaccine-funding-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 8462
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-novavax-covid-19-vaccine-funding-agreement-9/
            [children] => 
        )

    [business-model.benefit-revenue-sharing.cepi-novavax-covid-19-vaccine-funding-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 66
            [slug] => benefit-revenue-sharing
            [title] => Benefit sharing
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Benefit sharing
            [provision_id] => 4204
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-novavax-covid-19-vaccine-funding-agreement-4/
            [children] => 
        )

    [business-model.regulatory-strategy.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 2889
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4/
            [children] => 
        )

    [business-model.roles-responsibilities.cepi-novavax-covid-19-vaccine-funding-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4200
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-novavax-covid-19-vaccine-funding-agreement-2/
            [children] => 
        )

    [business-model.royalties-and-payments.cepi-novavax-covid-19-vaccine-funding-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3493
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-novavax-covid-19-vaccine-funding-agreement/
            [children] => 
        )

    [business-model.supply-purchase-of-products.cepi-novavax-covid-19-vaccine-funding-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 5653
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-novavax-covid-19-vaccine-funding-agreement-7/
            [children] => 
        )

    [information-sharing.confidentiality.cepi-novavax-covid-19-vaccine-funding-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4205
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-novavax-covid-19-vaccine-funding-agreement-5/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.cepi-novavax-covid-19-vaccine-funding-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4201
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-novavax-covid-19-vaccine-funding-agreement-3/
            [children] => 
        )

    [information-sharing.publication-of-results.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 2893
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7/
            [children] => 
        )

    [ip-ownership.license-grants.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 2890
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5/
            [children] => 
        )

    [ip-ownership.ownership-ip.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 2885
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement/
            [children] => 
        )

    [ip-ownership.protection-results.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 2885
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement/
            [children] => 
        )

    [liability.indemnity.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 2908
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9/
            [children] => 
        )

    [liability.insurance.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 2908
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9/
            [children] => 
        )

    [liability.warranties.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 2907
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8/
            [children] => 
        )

    [term-and-termination.effect-of-termination.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 2909
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10/
            [children] => 
        )

    [term-and-termination.term-of-agreement.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 2909
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 2909
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10/
            [children] => 
        )

)
CEPI - Valneva, Chikungunya Vaccine Funding Agreement
2019
Funder
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Array
(
    [access-to-medicines.ensuring-continuity.cepi-valneva-chikungunya-vaccine-funding-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 3748
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-10/
            [children] => 
        )

    [access-to-medicines.equitable-access.cepi-valneva-chikungunya-vaccine-funding-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 8467
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-2/
            [children] => 
        )

    [access-to-medicines.outbreak-preparedness.cepi-valneva-chikungunya-vaccine-funding-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 102
            [slug] => outbreak-preparedness
            [title] => Preparedness & response
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Preparedness & response
            [provision_id] => 3724
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-3/
            [children] => 
        )

    [access-to-medicines.pricing.cepi-valneva-chikungunya-vaccine-funding-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 8468
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-13/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.cepi-valneva-chikungunya-vaccine-funding-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 3726
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-5/
            [children] => 
        )

    [business-model.benefit-revenue-sharing.cepi-valneva-chikungunya-vaccine-funding-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 66
            [slug] => benefit-revenue-sharing
            [title] => Benefit sharing
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Benefit sharing
            [provision_id] => 3747
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-9/
            [children] => 
        )

    [business-model.regulatory-strategy.cepi-valneva-chikungunya-vaccine-funding-agreement-20] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 8484
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-20/
            [children] => 
        )

    [business-model.roles-responsibilities.cepi-valneva-chikungunya-vaccine-funding-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 3756
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-17/
            [children] => 
        )

    [business-model.royalties-and-payments.cepi-valneva-chikungunya-vaccine-funding-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3722
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement/
            [children] => 
        )

    [information-sharing.confidentiality.cepi-valneva-chikungunya-vaccine-funding-agreement-18] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3757
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-18/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.cepi-valneva-chikungunya-vaccine-funding-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3725
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-4/
            [children] => 
        )

    [information-sharing.publication-of-results.cepi-valneva-chikungunya-vaccine-funding-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 3744
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-7/
            [children] => 
        )

    [information-sharing.technology-transfer.cepi-valneva-chikungunya-vaccine-funding-agreement-19] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 8469
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-19/
            [children] => 
        )

    [ip-ownership.license-grants.cepi-valneva-chikungunya-vaccine-funding-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 3748
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-10/
            [children] => 
        )

    [ip-ownership.ownership-ip.cepi-valneva-chikungunya-vaccine-funding-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 3743
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-6/
            [children] => 
        )

    [ip-ownership.protection-results.cepi-valneva-chikungunya-vaccine-funding-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 3746
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-8/
            [children] => 
        )

    [liability.indemnity.cepi-valneva-chikungunya-vaccine-funding-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3751
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-12/
            [children] => 
        )

    [liability.insurance.cepi-valneva-chikungunya-vaccine-funding-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 3753
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-14/
            [children] => 
        )

    [liability.warranties.cepi-valneva-chikungunya-vaccine-funding-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3749
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-11/
            [children] => 
        )

    [term-and-termination.effect-of-termination.cepi-valneva-chikungunya-vaccine-funding-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 3755
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-16/
            [children] => 
        )

    [term-and-termination.term-of-agreement.cepi-valneva-chikungunya-vaccine-funding-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3754
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-15/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.cepi-valneva-chikungunya-vaccine-funding-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 3754
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-15/
            [children] => 
        )

)
CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
2021
Funder
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Array
(
    [access-to-medicines.ensuring-continuity.cepi-vbi-covid-19-vaccine-development-funding-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 8151
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-8/
            [children] => 
        )

    [access-to-medicines.equitable-access.cepi-vbi-covid-19-vaccine-development-funding-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 8051
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement/
            [children] => 
        )

    [access-to-medicines.outbreak-preparedness.cepi-vbi-covid-19-vaccine-development-funding-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 102
            [slug] => outbreak-preparedness
            [title] => Preparedness & response
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Preparedness & response
            [provision_id] => 8130
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-3/
            [children] => 
        )

    [access-to-medicines.pricing.cepi-vbi-covid-19-vaccine-development-funding-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 8129
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-2/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.cepi-vbi-covid-19-vaccine-development-funding-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 8131
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-4/
            [children] => 
        )

    [business-model.benefit-revenue-sharing.cepi-vbi-covid-19-vaccine-development-funding-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 66
            [slug] => benefit-revenue-sharing
            [title] => Benefit sharing
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Benefit sharing
            [provision_id] => 8190
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-11/
            [children] => 
        )

    [business-model.regulatory-strategy.cepi-vbi-covid-19-vaccine-development-funding-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 8192
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-13/
            [children] => 
        )

    [business-model.roles-responsibilities.cepi-vbi-covid-19-vaccine-development-funding-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 8143
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-6/
            [children] => 
        )

    [business-model.royalties-and-payments.cepi-vbi-covid-19-vaccine-development-funding-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 8191
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-12/
            [children] => 
        )

    [business-model.supply-purchase-of-products.cepi-vbi-covid-19-vaccine-development-funding-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 8131
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-4/
            [children] => 
        )

    [information-sharing.confidentiality.cepi-vbi-covid-19-vaccine-development-funding-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 8152
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-9/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.cepi-vbi-covid-19-vaccine-development-funding-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 8142
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-5/
            [children] => 
        )

    [information-sharing.publication-of-results.cepi-vbi-covid-19-vaccine-development-funding-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 8157
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-10/
            [children] => 
        )

    [ip-ownership.license-grants.cepi-vbi-covid-19-vaccine-development-funding-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 8150
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-7/
            [children] => 
        )

    [ip-ownership.ownership-ip.cepi-vbi-covid-19-vaccine-development-funding-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 8150
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-7/
            [children] => 
        )

    [ip-ownership.protection-results.cepi-vbi-covid-19-vaccine-development-funding-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 8150
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-7/
            [children] => 
        )

    [liability.indemnity.cepi-vbi-covid-19-vaccine-development-funding-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 8311
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-14/
            [children] => 
        )

    [liability.insurance.cepi-vbi-covid-19-vaccine-development-funding-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 8311
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-14/
            [children] => 
        )

    [liability.warranties.cepi-vbi-covid-19-vaccine-development-funding-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 8312
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-15/
            [children] => 
        )

    [term-and-termination.effect-of-termination.cepi-vbi-covid-19-vaccine-development-funding-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 8314
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-17/
            [children] => 
        )

    [term-and-termination.term-of-agreement.cepi-vbi-covid-19-vaccine-development-funding-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 8313
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-16/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.cepi-vbi-covid-19-vaccine-development-funding-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 8314
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-17/
            [children] => 
        )

)
CEPI CfP3i Vaccine Funding Agreement Template
2018
Funder
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Array
(
    [access-to-medicines.ensuring-continuity.cepi-cfp3i-template-funding-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 1205
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-4/
            [children] => 
        )

    [access-to-medicines.equitable-access.cepi-cfp3i-template-funding-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 1202
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-6/
            [children] => 
        )

    [access-to-medicines.outbreak-preparedness.cepi-cfp3i-template-funding-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 102
            [slug] => outbreak-preparedness
            [title] => Preparedness & response
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Preparedness & response
            [provision_id] => 1204
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-5/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.cepi-cfp3i-template-funding-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 8480
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-9/
            [children] => 
        )

    [business-model.benefit-revenue-sharing.cepi-cfp3i-template-funding-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 66
            [slug] => benefit-revenue-sharing
            [title] => Benefit sharing
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Benefit sharing
            [provision_id] => 1203
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-3/
            [children] => 
        )

    [business-model.regulatory-strategy.cepi-cfp3i-template-funding-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 8482
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-11/
            [children] => 
        )

    [business-model.roles-responsibilities.cepi-cfp3i-template-funding-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 8479
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-2/
            [children] => 
        )

    [business-model.royalties-and-payments.cepi-cfp3i-template-funding-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 8481
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-10/
            [children] => 
        )

    [information-sharing.confidentiality.cepi-cfp3i-vaccine-funding-agreement-template] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 8491
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-vaccine-funding-agreement-template/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.cepi-cfp3i-template-funding-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3736
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement/
            [children] => 
        )

    [information-sharing.publication-of-results.cepi-cfpi3-template-funding-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 1221
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfpi3-template-funding-agreement/
            [children] => 
        )

    [information-sharing.technology-transfer.cepi-cfp3i-template-funding-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 8485
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-12/
            [children] => 
        )

    [ip-ownership.license-grants.cepi-cfp3i-template-funding-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 1205
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-4/
            [children] => 
        )

    [ip-ownership.ownership-ip.cepi-cfp3i-template-funding-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 1159
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-7/
            [children] => 
        )

    [ip-ownership.protection-results.cepi-cfp3i-template-funding-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 996
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-8/
            [children] => 
        )

    [liability.indemnity.cepi-cfp3i-template-funding-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 8487
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-14/
            [children] => 
        )

    [liability.insurance.cepi-cfp3i-template-funding-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 8488
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-15/
            [children] => 
        )

    [liability.warranties.cepi-cfp3i-template-funding-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 8486
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-13/
            [children] => 
        )

    [term-and-termination.effect-of-termination.cepi-cfp3i-template-funding-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 8490
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-17/
            [children] => 
        )

    [term-and-termination.term-of-agreement.cepi-cfp3i-template-funding-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 8489
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-16/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.cepi-cfp3i-template-funding-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 8489
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-16/
            [children] => 
        )

)
CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
2021
Government
Multilateral organization
Diagnostic
Commercialization
Array
(
    [access-to-medicines.pricing.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 4796
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement/
            [children] => 
        )

    [business-model.roles-responsibilities.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4806
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-9/
            [children] => 
        )

    [business-model.royalties-and-payments.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 4798
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-3/
            [children] => 
        )

    [information-sharing.confidentiality.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4800
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4808
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-11/
            [children] => 
        )

    [information-sharing.technology-transfer.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 4801
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-5/
            [children] => 
        )

    [ip-ownership.license-grants.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 4796
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement/
            [children] => 
        )

    [ip-ownership.protection-results.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 4797
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-2/
            [children] => 
        )

    [liability.warranties.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4802
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-6/
            [children] => 
        )

    [term-and-termination.effect-of-termination.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4807
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-10/
            [children] => 
        )

    [term-and-termination.term-of-agreement.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 4804
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-7/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 4805
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-8/
            [children] => 
        )

)
CSIC - MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
2023
Government
Multilateral organization
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.pricing.csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 11251
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-4/
            [children] => 
        )

    [business-model.roles-responsibilities.csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 11257
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-9/
            [children] => 
        )

    [business-model.royalties-and-payments.csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 11256
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-8/
            [children] => 
        )

    [information-sharing.confidentiality.csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 11252
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-5/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 11254
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-6/
            [children] => 
        )

    [information-sharing.technology-transfer.csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 11255
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-7/
            [children] => 
        )

    [ip-ownership.license-grants.csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 11248
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-2/
            [children] => 
        )

    [ip-ownership.ownership-ip.csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 11247
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement/
            [children] => 
        )

    [ip-ownership.protection-results.csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 11250
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-3/
            [children] => 
        )

    [liability.indemnity.csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 11258
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-10/
            [children] => 
        )

    [liability.warranties.csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 11259
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-11/
            [children] => 
        )

    [term-and-termination.effect-of-termination.csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 11260
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-12/
            [children] => 
        )

    [term-and-termination.term-of-agreement.csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 11260
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-12/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 11260
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-12/
            [children] => 
        )

)
CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
2021
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [business-model.regulatory-strategy.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 4002
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-3/
            [children] => 
        )

    [business-model.roles-responsibilities.curevac-and-gsk-collaboration-and-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4009
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-and-gsk-collaboration-and-license-agreement-2/
            [children] => 
        )

    [business-model.royalties-and-payments.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 4004
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-5/
            [children] => 
        )

    [business-model.supply-purchase-of-products.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 4007
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-8/
            [children] => 
        )

    [information-sharing.confidentiality.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4013
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-12/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4003
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-4/
            [children] => 
        )

    [information-sharing.publication-of-results.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 4014
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-13/
            [children] => 
        )

    [information-sharing.technology-transfer.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 4006
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-7/
            [children] => 
        )

    [ip-ownership.license-grants.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 4001
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-2/
            [children] => 
        )

    [ip-ownership.ownership-ip.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 4011
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-10/
            [children] => 
        )

    [ip-ownership.protection-results.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 3997
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement/
            [children] => 
        )

    [liability.indemnity.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 4016
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-15/
            [children] => 
        )

    [liability.insurance.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-22] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 4024
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-22/
            [children] => 
        )

    [liability.warranties.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4017
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-16/
            [children] => 
        )

    [term-and-termination.effect-of-termination.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-20] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4022
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-20/
            [children] => 
        )

    [term-and-termination.term-of-agreement.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-18] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 4020
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-18/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-19] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 4021
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-19/
            [children] => 
        )

)
DNDi - BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
2009
Industry
Product development partnership
Drug
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.territory-access-commitments.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 6317
            [provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-4/
            [children] => 
        )

    [business-model.regulatory-strategy.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 6326
            [provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-11/
            [children] => 
        )

    [business-model.roles-responsibilities.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 6325
            [provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-10/
            [children] => 
        )

    [business-model.royalties-and-payments.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 6324
            [provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-9/
            [children] => 
        )

    [business-model.supply-purchase-of-products.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 6323
            [provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-8/
            [children] => 
        )

    [information-sharing.confidentiality.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 6318
            [provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-5/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 6322
            [provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-7/
            [children] => 
        )

    [information-sharing.publication-of-results.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 6319
            [provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-6/
            [children] => 
        )

    [information-sharing.technology-transfer.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 6322
            [provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-7/
            [children] => 
        )

    [ip-ownership.license-grants.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 6316
            [provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-3/
            [children] => 
        )

    [ip-ownership.ownership-ip.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 6314
            [provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement/
            [children] => 
        )

    [ip-ownership.protection-results.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 6315
            [provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-2/
            [children] => 
        )

    [liability.indemnity.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 6327
            [provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-12/
            [children] => 
        )

    [liability.insurance.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 6328
            [provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-13/
            [children] => 
        )

    [liability.warranties.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 6329
            [provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-14/
            [children] => 
        )

    [term-and-termination.effect-of-termination.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 6333
            [provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-17/
            [children] => 
        )

    [term-and-termination.term-of-agreement.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 6330
            [provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-15/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 6332
            [provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-16/
            [children] => 
        )

)
DNDi Template Development Collaboration and License Agreement
2023
Academic institution
Industry
Product development partnership
Drug
Early clinical (through Phase 2)
Late clinical (Phase 3)
Array
(
    [access-to-medicines.ensuring-continuity.dndi-template-development-collaboration-and-license-agreement-18] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 9893
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-development-collaboration-and-license-agreement-18/
            [children] => 
        )

    [access-to-medicines.equitable-access.dndi-template-development-collaboration-and-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 9873
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-development-collaboration-and-license-agreement/
            [children] => 
        )

    [access-to-medicines.pricing.dndi-template-development-collaboration-and-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 9874
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-development-collaboration-and-license-agreement-2/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.dndi-template-development-collaboration-and-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 9877
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-development-collaboration-and-license-agreement-4/
            [children] => 
        )

    [business-model.benefit-revenue-sharing.dndi-template-development-collaboration-and-license-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 66
            [slug] => benefit-revenue-sharing
            [title] => Benefit sharing
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Benefit sharing
            [provision_id] => 9880
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-development-collaboration-and-license-agreement-6/
            [children] => 
        )

    [business-model.regulatory-strategy.dndi-template-development-collaboration-and-license-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 9879
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-development-collaboration-and-license-agreement-5/
            [children] => 
        )

    [business-model.roles-responsibilities.dndi-template-development-collaboration-and-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 9875
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-development-collaboration-and-license-agreement-3/
            [children] => 
        )

    [business-model.royalties-and-payments.dndi-template-development-collaboration-and-license-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 9882
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-development-collaboration-and-license-agreement-8/
            [children] => 
        )

    [business-model.supply-purchase-of-products.dndi-template-development-collaboration-and-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 9877
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-development-collaboration-and-license-agreement-4/
            [children] => 
        )

    [information-sharing.confidentiality.dndi-template-development-collaboration-and-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 9886
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-development-collaboration-and-license-agreement-12/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.dndi-template-development-collaboration-and-license-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 9883
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-development-collaboration-and-license-agreement-9/
            [children] => 
        )

    [information-sharing.publication-of-results.dndi-template-development-collaboration-and-license-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 9888
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-development-collaboration-and-license-agreement-13/
            [children] => 
        )

    [information-sharing.technology-transfer.dndi-template-development-collaboration-and-license-agreement-19] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 9894
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-development-collaboration-and-license-agreement-19/
            [children] => 
        )

    [ip-ownership.license-grants.dndi-template-development-collaboration-and-license-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 9885
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-development-collaboration-and-license-agreement-11/
            [children] => 
        )

    [ip-ownership.ownership-ip.dndi-template-development-collaboration-and-license-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 9884
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-development-collaboration-and-license-agreement-10/
            [children] => 
        )

    [ip-ownership.protection-results.dndi-template-development-collaboration-and-license-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 9884
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-development-collaboration-and-license-agreement-10/
            [children] => 
        )

    [liability.indemnity.dndi-template-development-collaboration-and-license-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 9889
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-development-collaboration-and-license-agreement-14/
            [children] => 
        )

    [liability.warranties.dndi-template-development-collaboration-and-license-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 9881
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-development-collaboration-and-license-agreement-7/
            [children] => 
        )

    [term-and-termination.effect-of-termination.dndi-template-development-collaboration-and-license-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 9892
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-development-collaboration-and-license-agreement-17/
            [children] => 
        )

    [term-and-termination.term-of-agreement.dndi-template-development-collaboration-and-license-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 9890
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-development-collaboration-and-license-agreement-15/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.dndi-template-development-collaboration-and-license-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 9891
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-development-collaboration-and-license-agreement-16/
            [children] => 
        )

)
DNDi Template Research Collaboration and License Agreement
2023
Academic institution
Industry
Product development partnership
Drug
Discovery/Concept
Preclinical
Array
(
    [access-to-medicines.equitable-access.dndi-template-research-collaboration-and-license-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 9859
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-research-collaboration-and-license-agreement-7/
            [children] => 
        )

    [access-to-medicines.pricing.dndi-template-research-collaboration-and-license-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 9860
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-research-collaboration-and-license-agreement-6/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.dndi-template-research-collaboration-and-license-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 9860
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-research-collaboration-and-license-agreement-6/
            [children] => 
        )

    [business-model.roles-responsibilities.dndi-template-research-collaboration-and-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 9861
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-research-collaboration-and-license-agreement/
            [children] => 
        )

    [business-model.royalties-and-payments.dndi-template-research-collaboration-and-license-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 9862
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-research-collaboration-and-license-agreement-5/
            [children] => 
        )

    [information-sharing.confidentiality.dndi-template-research-collaboration-and-license-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 9866
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-research-collaboration-and-license-agreement-13/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.dndi-template-research-collaboration-and-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 9863
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-research-collaboration-and-license-agreement-3/
            [children] => 
        )

    [information-sharing.publication-of-results.dndi-template-research-collaboration-and-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 9867
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-research-collaboration-and-license-agreement-12/
            [children] => 
        )

    [ip-ownership.license-grants.dndi-template-research-collaboration-and-license-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 9865
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-research-collaboration-and-license-agreement-14/
            [children] => 
        )

    [ip-ownership.ownership-ip.dndi-template-research-collaboration-and-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 9864
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-research-collaboration-and-license-agreement-4/
            [children] => 
        )

    [ip-ownership.protection-results.dndi-template-research-collaboration-and-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 9864
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-research-collaboration-and-license-agreement-4/
            [children] => 
        )

    [liability.indemnity.dndi-template-research-collaboration-and-license-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 9869
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-research-collaboration-and-license-agreement-10/
            [children] => 
        )

    [liability.warranties.dndi-template-research-collaboration-and-license-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 9868
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-research-collaboration-and-license-agreement-11/
            [children] => 
        )

    [term-and-termination.effect-of-termination.dndi-template-research-collaboration-and-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 9872
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-research-collaboration-and-license-agreement-2/
            [children] => 
        )

    [term-and-termination.term-of-agreement.dndi-template-research-collaboration-and-license-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 9870
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-research-collaboration-and-license-agreement-9/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.dndi-template-research-collaboration-and-license-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 9871
            [provision_permalink] => https://ghiaa.org/provision_document/dndi-template-research-collaboration-and-license-agreement-8/
            [children] => 
        )

)
DNDi/GARDP - Entasis, Gonorrhoea Medication, Collaboration Agreement
2017
Industry
Product development partnership
Drug
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.equitable-access.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 4877
            [provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-3/
            [children] => 
        )

    [access-to-medicines.pricing.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 4877
            [provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-3/
            [children] => 
        )

    [business-model.benefit-revenue-sharing.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 66
            [slug] => benefit-revenue-sharing
            [title] => Benefit sharing
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Benefit sharing
            [provision_id] => 4894
            [provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-17/
            [children] => 
        )

    [business-model.regulatory-strategy.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 4893
            [provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-16/
            [children] => 
        )

    [business-model.roles-responsibilities.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4892
            [provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-15/
            [children] => 
        )

    [business-model.supply-purchase-of-products.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 4884
            [provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-8/
            [children] => 
        )

    [information-sharing.confidentiality.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4878
            [provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4882
            [provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-6/
            [children] => 
        )

    [information-sharing.publication-of-results.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 4881
            [provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-5/
            [children] => 
        )

    [information-sharing.technology-transfer.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 4883
            [provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-7/
            [children] => 
        )

    [ip-ownership.license-grants.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 4875
            [provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement/
            [children] => 
        )

    [ip-ownership.ownership-ip.entasis-dndi-gardp-gonorrhea-medication-collaboration-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 4873
            [provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhea-medication-collaboration-agreement/
            [children] => 
        )

    [ip-ownership.protection-results.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 4876
            [provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-2/
            [children] => 
        )

    [liability.indemnity.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 4885
            [provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-9/
            [children] => 
        )

    [liability.insurance.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 4886
            [provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-10/
            [children] => 
        )

    [liability.warranties.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4888
            [provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-11/
            [children] => 
        )

    [term-and-termination.effect-of-termination.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4891
            [provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-14/
            [children] => 
        )

    [term-and-termination.term-of-agreement.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 4889
            [provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-12/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 4890
            [provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-13/
            [children] => 
        )

)
Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
2021
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
    [business-model.regulatory-strategy.pfizer-biontech-dominican-republic-binding-term-sheet-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 3120
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-2/
            [children] => 
        )

    [business-model.roles-responsibilities.pfizer-biontech-dominican-republic-binding-term-sheet-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 3125
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-7/
            [children] => 
        )

    [business-model.supply-purchase-of-products.pfizer-biontech-dominican-republic-binding-term-sheet-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 3121
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-3/
            [children] => 
        )

    [information-sharing.confidentiality.pfizer-biontech-dominican-republic-binding-term-sheet-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3122
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.pfizer-biontech-dominican-republic-binding-term-sheet-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3127
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-9/
            [children] => 
        )

    [ip-ownership.ownership-ip.pfizer-biontech-dominican-republic-binding-term-sheet] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 3119
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet/
            [children] => 
        )

    [liability.indemnity.pfizer-biontech-dominican-republic-binding-term-sheet-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3123
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-5/
            [children] => 
        )

    [liability.warranties.pfizer-biontech-dominican-republic-binding-term-sheet-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3123
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-5/
            [children] => 
        )

    [term-and-termination.term-of-agreement.pfizer-biontech-dominican-republic-binding-term-sheet-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3126
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-8/
            [children] => 
        )

)
Elkurt - Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
2021
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 4838
            [provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-5/
            [children] => 
        )

    [access-to-medicines.pricing.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 4838
            [provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-5/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 4838
            [provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-5/
            [children] => 
        )

    [business-model.roles-responsibilities.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4850
            [provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-16/
            [children] => 
        )

    [business-model.royalties-and-payments.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 4842
            [provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-8/
            [children] => 
        )

    [information-sharing.confidentiality.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4841
            [provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-7/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4849
            [provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-15/
            [children] => 
        )

    [ip-ownership.license-grants.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 4835
            [provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-2/
            [children] => 
        )

    [ip-ownership.protection-results.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 4837
            [provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-4/
            [children] => 
        )

    [liability.indemnity.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 4843
            [provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-9/
            [children] => 
        )

    [liability.insurance.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 4844
            [provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-10/
            [children] => 
        )

    [liability.warranties.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4845
            [provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-11/
            [children] => 
        )

    [term-and-termination.effect-of-termination.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4848
            [provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-14/
            [children] => 
        )

    [term-and-termination.term-of-agreement.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 4846
            [provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-12/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 4847
            [provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-13/
            [children] => 
        )

)
European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.donation.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 271
            [slug] => donation
            [title] => Donation
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Donation
            [provision_id] => 2540
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11/
            [children] => 
        )

    [access-to-medicines.ensuring-continuity.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 2544
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8/
            [children] => 
        )

    [business-model.regulatory-strategy.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 2541
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10/
            [children] => 
        )

    [business-model.roles-responsibilities.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 2545
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7/
            [children] => 
        )

    [business-model.royalties-and-payments.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 2543
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12/
            [children] => 
        )

    [business-model.supply-purchase-of-products.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 2540
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11/
            [children] => 
        )

    [information-sharing.confidentiality.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 2549
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 2541
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10/
            [children] => 
        )

    [ip-ownership.ownership-ip.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 2544
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8/
            [children] => 
        )

    [liability.indemnity.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 2547
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5/
            [children] => 
        )

    [liability.warranties.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 2542
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9/
            [children] => 
        )

    [term-and-termination.effect-of-termination.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 2553
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2/
            [children] => 
        )

    [term-and-termination.term-of-agreement.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 2553
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 2553
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2/
            [children] => 
        )

)
European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.donation.curevac-ec-covid-19-vaccine-advance-purchase-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 271
            [slug] => donation
            [title] => Donation
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Donation
            [provision_id] => 2471
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement/
            [children] => 
        )

    [access-to-medicines.outbreak-preparedness.curevac-ec-covid-19-vaccine-advance-purchase-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 102
            [slug] => outbreak-preparedness
            [title] => Preparedness & response
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Preparedness & response
            [provision_id] => 2470
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-14/
            [children] => 
        )

    [business-model.regulatory-strategy.curevac-ec-covid-19-vaccine-advance-purchase-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 2473
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-12/
            [children] => 
        )

    [business-model.roles-responsibilities.curevac-ec-covid-19-vaccine-advance-purchase-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 2477
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-8/
            [children] => 
        )

    [business-model.royalties-and-payments.curevac-ec-covid-19-vaccine-advance-purchase-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 2475
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-10/
            [children] => 
        )

    [business-model.supply-purchase-of-products.curevac-ec-covid-19-vaccine-advance-purchase-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 2471
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement/
            [children] => 
        )

    [information-sharing.confidentiality.curevac-ec-covid-19-vaccine-advance-purchase-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 2481
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.european-commission-curevac-covid-19-vaccine-advance-purchase-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3741
            [provision_permalink] => https://ghiaa.org/provision_document/european-commission-curevac-covid-19-vaccine-advance-purchase-agreement/
            [children] => 
        )

    [ip-ownership.ownership-ip.curevac-ec-covid-19-vaccine-advance-purchase-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 2476
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-9/
            [children] => 
        )

    [liability.indemnity.curevac-ec-covid-19-vaccine-advance-purchase-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 2479
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-6/
            [children] => 
        )

    [liability.warranties.curevac-ec-covid-19-vaccine-advance-purchase-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 2474
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-11/
            [children] => 
        )

    [term-and-termination.effect-of-termination.european-commission-curevac-covid-19-vaccine-advance-purchase-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4058
            [provision_permalink] => https://ghiaa.org/provision_document/european-commission-curevac-covid-19-vaccine-advance-purchase-agreement-2/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.curevac-ec-covid-19-vaccine-advance-purchase-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 2482
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-3/
            [children] => 
        )

)
FIND Sample Funding Terms and Conditions
2021
Academic institution
Industry
Product development partnership
Diagnostic
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.equitable-access.find-sample-funding-terms-and-conditions] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 7562
            [provision_permalink] => https://ghiaa.org/provision_document/find-sample-funding-terms-and-conditions/
            [children] => 
        )

    [access-to-medicines.pricing.find-sample-funding-terms-and-conditions-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 7563
            [provision_permalink] => https://ghiaa.org/provision_document/find-sample-funding-terms-and-conditions-2/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.find-sample-funding-terms-and-conditions-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 7567
            [provision_permalink] => https://ghiaa.org/provision_document/find-sample-funding-terms-and-conditions-3/
            [children] => 
        )

    [business-model.regulatory-strategy.find-sample-funding-terms-and-conditions-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 7580
            [provision_permalink] => https://ghiaa.org/provision_document/find-sample-funding-terms-and-conditions-7/
            [children] => 
        )

    [business-model.roles-responsibilities.find-sample-funding-terms-and-conditions-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 7570
            [provision_permalink] => https://ghiaa.org/provision_document/find-sample-funding-terms-and-conditions-6/
            [children] => 
        )

    [information-sharing.publication-of-results.find-sample-funding-terms-and-conditions-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 7568
            [provision_permalink] => https://ghiaa.org/provision_document/find-sample-funding-terms-and-conditions-4/
            [children] => 
        )

    [information-sharing.technology-transfer.find-sample-funding-terms-and-conditions-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 7569
            [provision_permalink] => https://ghiaa.org/provision_document/find-sample-funding-terms-and-conditions-5/
            [children] => 
        )

    [ip-ownership.license-grants.find-sample-funding-terms-and-conditions-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 7569
            [provision_permalink] => https://ghiaa.org/provision_document/find-sample-funding-terms-and-conditions-5/
            [children] => 
        )

    [liability.indemnity.find-sample-funding-terms-and-conditions-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 7581
            [provision_permalink] => https://ghiaa.org/provision_document/find-sample-funding-terms-and-conditions-8/
            [children] => 
        )

    [liability.warranties.find-sample-funding-terms-and-conditions-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 7582
            [provision_permalink] => https://ghiaa.org/provision_document/find-sample-funding-terms-and-conditions-9/
            [children] => 
        )

)
Fiocruz - AstraZeneca, COVID-19 Technological Order Agreement
2021
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.territory-access-commitments.fiocruz-astrazeneca-covid-19-technological-order-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 3420
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement/
            [children] => 
        )

    [business-model.regulatory-strategy.fiocruz-astrazeneca-covid-19-technological-order-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 3424
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-4/
            [children] => 
        )

    [business-model.roles-responsibilities.fiocruz-astrazeneca-covid-19-technological-order-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 3427
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-6/
            [children] => 
        )

    [business-model.royalties-and-payments.fiocruz-astrazeneca-covid-19-technological-order-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3433
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-10/
            [children] => 
        )

    [information-sharing.confidentiality.fiocruz-astrazeneca-covid-19-technological-order-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3434
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-11/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.fiocruz-astrazeneca-covid-19-technological-order-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3428
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-7/
            [children] => 
        )

    [information-sharing.technology-transfer.fiocruz-astrazeneca-covid-19-technological-order-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 3421
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-2/
            [children] => 
        )

    [ip-ownership.license-grants.fiocruz-astrazeneca-covid-19-technological-order-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 3422
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-3/
            [children] => 
        )

    [liability.indemnity.fiocruz-astrazeneca-covid-19-technological-order-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3436
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-13/
            [children] => 
        )

    [liability.warranties.fiocruz-astrazeneca-covid-19-technological-order-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3430
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-8/
            [children] => 
        )

    [term-and-termination.effect-of-termination.fiocruz-astrazeneca-covid-19-technological-order-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4601
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-12/
            [children] => 
        )

    [term-and-termination.term-of-agreement.fiocruz-astrazeneca-covid-19-technological-order-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3426
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-5/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.fiocruz-astrazeneca-covid-19-technological-order-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 3431
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-9/
            [children] => 
        )

)
Fiocruz - AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
2021
Government
Industry
Vaccine
Commercialization
Array
(
    [access-to-medicines.donation.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 271
            [slug] => donation
            [title] => Donation
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Donation
            [provision_id] => 3849
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-5/
            [children] => 
        )

    [access-to-medicines.pricing.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 3848
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-4/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 3855
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-11/
            [children] => 
        )

    [business-model.regulatory-strategy.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-19] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 3863
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-19/
            [children] => 
        )

    [business-model.roles-responsibilities.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 3861
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-17/
            [children] => 
        )

    [business-model.supply-purchase-of-products.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 3855
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-11/
            [children] => 
        )

    [information-sharing.confidentiality.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3851
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-7/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3856
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-12/
            [children] => 
        )

    [information-sharing.publication-of-results.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 3852
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-8/
            [children] => 
        )

    [information-sharing.technology-transfer.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 3854
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-10/
            [children] => 
        )

    [ip-ownership.license-grants.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 3847
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-3/
            [children] => 
        )

    [ip-ownership.ownership-ip.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 3847
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-3/
            [children] => 
        )

    [ip-ownership.protection-results.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 3846
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-2/
            [children] => 
        )

    [liability.warranties.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3857
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-13/
            [children] => 
        )

    [term-and-termination.effect-of-termination.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 3860
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-16/
            [children] => 
        )

    [term-and-termination.term-of-agreement.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3858
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-14/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 3859
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-15/
            [children] => 
        )

)
Funder Development Partnering Agreement Template
2018
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [access-to-medicines.ensuring-continuity.funder-development-partnering-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 1201
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-8/
            [children] => 
        )

    [access-to-medicines.equitable-access.funder-development-partnering-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 1199
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-7/
            [children] => 
        )

    [access-to-medicines.outbreak-preparedness.funder-development-partnering-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 102
            [slug] => outbreak-preparedness
            [title] => Preparedness & response
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Preparedness & response
            [provision_id] => 1198
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-6/
            [children] => 
        )

    [access-to-medicines.pricing.funder-development-partnering-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 1199
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-7/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.funder-development-partnering-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 1199
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-7/
            [children] => 
        )

    [business-model.benefit-revenue-sharing.funder-development-partnering-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 66
            [slug] => benefit-revenue-sharing
            [title] => Benefit sharing
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Benefit sharing
            [provision_id] => 1200
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-9/
            [children] => 
        )

    [business-model.regulatory-strategy.funder-development-partnering-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 1184
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-5/
            [children] => 
        )

    [business-model.roles-responsibilities.funder-development-partnering-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 5812
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-12/
            [children] => 
        )

    [business-model.royalties-and-payments.funder-development-partnering-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 5810
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-4/
            [children] => 
        )

    [information-sharing.confidentiality.funder-development-partnering-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 5813
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-13/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.funder-development-partnering-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 5807
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-3/
            [children] => 
        )

    [information-sharing.publication-of-results.funder-development-partnering-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 5811
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-11/
            [children] => 
        )

    [ip-ownership.license-grants.funder-development-partnering-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 1201
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-8/
            [children] => 
        )

    [ip-ownership.ownership-ip.funder-development-partnering-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 1158
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-2/
            [children] => 
        )

    [ip-ownership.protection-results.funder-development-partnering-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 1139
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement/
            [children] => 
        )

    [liability.indemnity.funder-development-partnering-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1274
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-10/
            [children] => 
        )

    [liability.insurance.funder-development-partnering-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 5827
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-15/
            [children] => 
        )

    [liability.warranties.funder-development-partnering-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 5814
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-14/
            [children] => 
        )

    [term-and-termination.effect-of-termination.funder-development-partnering-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 5829
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-17/
            [children] => 
        )

    [term-and-termination.term-of-agreement.funder-development-partnering-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 5828
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-16/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.funder-development-partnering-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 5828
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-16/
            [children] => 
        )

)
GARDP – Orchid Pharma Ltd., Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
2023
Funder
Industry
Drug
Commercialization
Array
(
    [access-to-medicines.equitable-access.gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 11471
            [provision_permalink] => https://ghiaa.org/provision_document/gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-4/
            [children] => 
        )

    [access-to-medicines.pricing.gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 11472
            [provision_permalink] => https://ghiaa.org/provision_document/gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-6/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 11473
            [provision_permalink] => https://ghiaa.org/provision_document/gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-7/
            [children] => 
        )

    [business-model.regulatory-strategy.gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 11480
            [provision_permalink] => https://ghiaa.org/provision_document/gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-13/
            [children] => 
        )

    [business-model.roles-responsibilities.gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 11479
            [provision_permalink] => https://ghiaa.org/provision_document/gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-12/
            [children] => 
        )

    [business-model.supply-purchase-of-products.gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 11478
            [provision_permalink] => https://ghiaa.org/provision_document/gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-11/
            [children] => 
        )

    [information-sharing.confidentiality.gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 11474
            [provision_permalink] => https://ghiaa.org/provision_document/gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-8/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 11476
            [provision_permalink] => https://ghiaa.org/provision_document/gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-9/
            [children] => 
        )

    [information-sharing.technology-transfer.gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 11477
            [provision_permalink] => https://ghiaa.org/provision_document/gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-10/
            [children] => 
        )

    [ip-ownership.license-grants.gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 11468
            [provision_permalink] => https://ghiaa.org/provision_document/gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-2/
            [children] => 
        )

    [ip-ownership.ownership-ip.gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 11467
            [provision_permalink] => https://ghiaa.org/provision_document/gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-5/
            [children] => 
        )

    [ip-ownership.protection-results.gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 11470
            [provision_permalink] => https://ghiaa.org/provision_document/gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-3/
            [children] => 
        )

    [liability.indemnity.gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 11481
            [provision_permalink] => https://ghiaa.org/provision_document/gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-14/
            [children] => 
        )

    [liability.insurance.gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 11482
            [provision_permalink] => https://ghiaa.org/provision_document/gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-15/
            [children] => 
        )

    [liability.warranties.gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 11483
            [provision_permalink] => https://ghiaa.org/provision_document/gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-16/
            [children] => 
        )

    [term-and-termination.effect-of-termination.gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 11485
            [provision_permalink] => https://ghiaa.org/provision_document/gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement/
            [children] => 
        )

    [term-and-termination.term-of-agreement.gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 11485
            [provision_permalink] => https://ghiaa.org/provision_document/gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 11485
            [provision_permalink] => https://ghiaa.org/provision_document/gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement/
            [children] => 
        )

)
Gates Foundation - Arsanis RSV Monoclonal Antibodies Funding Agreement
2017
Funder
Industry
Drug
Preclinical
Array
(
    [access-to-medicines.ensuring-continuity.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 4681
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-2/
            [children] => 
        )

    [access-to-medicines.equitable-access.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 4680
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement/
            [children] => 
        )

    [business-model.royalties-and-payments.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 4684
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-5/
            [children] => 
        )

    [information-sharing.confidentiality.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4682
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-3/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4691
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-11/
            [children] => 
        )

    [information-sharing.publication-of-results.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 4683
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-4/
            [children] => 
        )

    [ip-ownership.license-grants.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 4681
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-2/
            [children] => 
        )

    [liability.indemnity.what-are-the-mechanisms-to-limit-exposure-to-additional-payments-or-expenses] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 4685
            [provision_permalink] => https://ghiaa.org/provision_document/what-are-the-mechanisms-to-limit-exposure-to-additional-payments-or-expenses/
            [children] => 
        )

    [liability.insurance.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 4686
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-6/
            [children] => 
        )

    [liability.warranties.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4687
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-7/
            [children] => 
        )

    [term-and-termination.effect-of-termination.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4690
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-10/
            [children] => 
        )

    [term-and-termination.term-of-agreement.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 4688
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-8/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 4689
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-9/
            [children] => 
        )

)
Gates Foundation - Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
2017
Funder
Industry
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 4695
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement/
            [children] => 
        )

    [access-to-medicines.equitable-access.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 4696
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-2/
            [children] => 
        )

    [access-to-medicines.pricing.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 4697
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-3/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 4697
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-3/
            [children] => 
        )

    [business-model.roles-responsibilities.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4704
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-10/
            [children] => 
        )

    [information-sharing.confidentiality.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4698
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4699
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-5/
            [children] => 
        )

    [information-sharing.publication-of-results.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 4699
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-5/
            [children] => 
        )

    [ip-ownership.license-grants.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 4695
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement/
            [children] => 
        )

    [liability.indemnity.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 4700
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-6/
            [children] => 
        )

    [liability.warranties.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4701
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-7/
            [children] => 
        )

    [term-and-termination.effect-of-termination.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4703
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-9/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 4702
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-8/
            [children] => 
        )

)
Gates Foundation - CureVac - GSK, Letter Agreement for Alignment on Global Access Commitments
2020
Funder
Industry
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 3378
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-4/
            [children] => 
        )

    [access-to-medicines.equitable-access.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 3375
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments/
            [children] => 
        )

    [information-sharing.confidentiality.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3379
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-5/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3377
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-3/
            [children] => 
        )

    [information-sharing.publication-of-results.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 3377
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-3/
            [children] => 
        )

    [ip-ownership.license-grants.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 3378
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-4/
            [children] => 
        )

    [ip-ownership.ownership-ip.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 4853
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-6/
            [children] => 
        )

    [liability.warranties.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4855
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-7/
            [children] => 
        )

    [term-and-termination.term-of-agreement.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3376
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-2/
            [children] => 
        )

)
Gates Foundation - CureVac, Global Access Commitments Agreement
2015
Funder
Industry
Drug
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [access-to-medicines.ensuring-continuity.bmgf-curevac-global-access-commitments-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 3357
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-8/
            [children] => 
        )

    [access-to-medicines.equitable-access.bmgf-curevac-global-access-commitments-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 3335
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement/
            [children] => 
        )

    [access-to-medicines.pricing.bmgf-curevac-global-access-commitments-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 3345
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-2/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.bmgf-curevac-global-access-commitments-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 3355
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-7/
            [children] => 
        )

    [business-model.roles-responsibilities.bmgf-curevac-global-access-commitments-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4857
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-15/
            [children] => 
        )

    [business-model.royalties-and-payments.bmgf-curevac-global-access-commitments-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3346
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-3/
            [children] => 
        )

    [information-sharing.confidentiality.bmgf-curevac-global-access-commitments-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3365
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-12/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.bmgf-curevac-global-access-commitments-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3353
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-6/
            [children] => 
        )

    [information-sharing.publication-of-results.bmgf-curevac-global-access-commitments-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 3350
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-5/
            [children] => 
        )

    [ip-ownership.ownership-ip.bmgf-curevac-global-access-commitments-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 3347
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-4/
            [children] => 
        )

    [ip-ownership.protection-results.bmgf-curevac-global-access-commitments-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 3347
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-4/
            [children] => 
        )

    [liability.indemnity.bmgf-curevac-global-access-commitments-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3367
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-13/
            [children] => 
        )

    [liability.insurance.bmgf-curevac-global-access-commitments-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 3362
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-11/
            [children] => 
        )

    [liability.warranties.bmgf-curevac-global-access-commitments-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3359
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-10/
            [children] => 
        )

    [term-and-termination.term-of-agreement.bmgf-curevac-global-access-commitments-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3358
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-9/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.bmgf-curevac-global-access-commitments-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 3369
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-14/
            [children] => 
        )

)
Gates Foundation - Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
2021
Funder
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 5592
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-2/
            [children] => 
        )

    [access-to-medicines.equitable-access.gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 5599
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-7/
            [children] => 
        )

    [access-to-medicines.pricing.gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 5593
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-3/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 5594
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-4/
            [children] => 
        )

    [business-model.supply-purchase-of-products.gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 5594
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-4/
            [children] => 
        )

    [information-sharing.publication-of-results.gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 5595
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-5/
            [children] => 
        )

    [ip-ownership.license-grants.gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 5592
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-2/
            [children] => 
        )

    [ip-ownership.ownership-ip.gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 5591
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement/
            [children] => 
        )

    [liability.warranties.gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 5596
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-6/
            [children] => 
        )

)
Gates Foundation - Icosavax, COVID-19 Vaccine Grant Agreement
2021
Funder
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Array
(
    [access-to-medicines.ensuring-continuity.gates-foundation-icosavax-covid-19-vaccine-grant-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 5608
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement/
            [children] => 
        )

    [access-to-medicines.equitable-access.gates-foundation-icosavax-covid-19-vaccine-grant-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 5609
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement-2/
            [children] => 
        )

    [business-model.royalties-and-payments.gates-foundation-icosavax-covid-19-vaccine-grant-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 5612
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement-5/
            [children] => 
        )

    [information-sharing.confidentiality.gates-foundation-icosavax-covid-19-vaccine-grant-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 5619
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement-11/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.gates-foundation-icosavax-covid-19-vaccine-grant-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 5611
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement-4/
            [children] => 
        )

    [information-sharing.publication-of-results.gates-foundation-icosavax-covid-19-vaccine-grant-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 5610
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement-3/
            [children] => 
        )

    [ip-ownership.license-grants.gates-foundation-icosavax-covid-19-vaccine-grant-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 5608
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement/
            [children] => 
        )

    [liability.indemnity.gates-foundation-icosavax-covid-19-vaccine-grant-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 5614
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement-6/
            [children] => 
        )

    [liability.insurance.gates-foundation-icosavax-covid-19-vaccine-grant-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 5615
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement-7/
            [children] => 
        )

    [liability.warranties.gates-foundation-icosavax-covid-19-vaccine-grant-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 5620
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement-12/
            [children] => 
        )

    [term-and-termination.effect-of-termination.gates-foundation-icosavax-covid-19-vaccine-grant-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 5618
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement-10/
            [children] => 
        )

    [term-and-termination.term-of-agreement.gates-foundation-icosavax-covid-19-vaccine-grant-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 5616
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement-8/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.gates-foundation-icosavax-covid-19-vaccine-grant-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 5617
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement-9/
            [children] => 
        )

)
Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
2015
Funder
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 6635
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-8/
            [children] => 
        )

    [access-to-medicines.equitable-access.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 6628
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement/
            [children] => 
        )

    [access-to-medicines.pricing.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 6632
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-5/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 6631
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-4/
            [children] => 
        )

    [business-model.roles-responsibilities.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 6630
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-3/
            [children] => 
        )

    [information-sharing.confidentiality.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 6638
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-11/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 6630
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-3/
            [children] => 
        )

    [information-sharing.publication-of-results.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 6629
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-2/
            [children] => 
        )

    [information-sharing.technology-transfer.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 6636
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-9/
            [children] => 
        )

    [liability.indemnity.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 6637
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-10/
            [children] => 
        )

    [liability.warranties.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 6633
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-6/
            [children] => 
        )

    [term-and-termination.effect-of-termination.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 6634
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-7/
            [children] => 
        )

    [term-and-termination.term-of-agreement.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 6634
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-7/
            [children] => 
        )

)
Gates Foundation - Visterra, Strategic Relationship Letter Agreement
2012
Funder
Industry
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.gates-foundation-visterra-strategic-relationship-letter-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 11269
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-visterra-strategic-relationship-letter-agreement-2/
            [children] => 
        )

    [access-to-medicines.equitable-access.gates-foundation-visterra-strategic-relationship-letter-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 11268
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-visterra-strategic-relationship-letter-agreement/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.gates-foundation-visterra-strategic-relationship-letter-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 11271
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-visterra-strategic-relationship-letter-agreement-4/
            [children] => 
        )

    [business-model.roles-responsibilities.gates-foundation-visterra-strategic-relationship-letter-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 11339
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-visterra-strategic-relationship-letter-agreement-8/
            [children] => 
        )

    [information-sharing.confidentiality.gates-foundation-visterra-strategic-relationship-letter-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 11272
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-visterra-strategic-relationship-letter-agreement-5/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.gates-foundation-visterra-strategic-relationship-letter-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 11270
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-visterra-strategic-relationship-letter-agreement-3/
            [children] => 
        )

    [ip-ownership.license-grants.gates-foundation-visterra-strategic-relationship-letter-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 11269
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-visterra-strategic-relationship-letter-agreement-2/
            [children] => 
        )

    [liability.indemnity.gates-foundation-visterra-strategic-relationship-letter-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 11273
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-visterra-strategic-relationship-letter-agreement-6/
            [children] => 
        )

    [term-and-termination.effect-of-termination.gates-foundation-visterra-strategic-relationship-letter-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 11274
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-visterra-strategic-relationship-letter-agreement-7/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.gates-foundation-visterra-strategic-relationship-letter-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 11274
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-visterra-strategic-relationship-letter-agreement-7/
            [children] => 
        )

)
Gates Foundation Sample Grant Terms & Conditions
2019
Academic institution
Funder
Industry
Product development partnership
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [access-to-medicines.ensuring-continuity.gates-global-access-commitment-and-humanitarian-license] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 1206
            [provision_permalink] => https://ghiaa.org/provision_document/gates-global-access-commitment-and-humanitarian-license/
            [children] => 
        )

    [access-to-medicines.equitable-access.gates-foundation-sample-grant-terms-conditions] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 4519
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-sample-grant-terms-conditions/
            [children] => 
        )

    [information-sharing.confidentiality.gates-foundation-sample-terms-conditions-for-project-support-grant-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 1395
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-sample-terms-conditions-for-project-support-grant-agreement-2/
            [children] => 
        )

    [information-sharing.publication-of-results.gates-foundation-sample-terms-conditions] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 1394
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-sample-terms-conditions/
            [children] => 
        )

    [ip-ownership.license-grants.gates-global-access-commitment-and-humanitarian-license] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 1206
            [provision_permalink] => https://ghiaa.org/provision_document/gates-global-access-commitment-and-humanitarian-license/
            [children] => 
        )

)
Gavi Alliance - Novavax, COVID-19 Vaccine Advance Purchase Agreement
2021
Industry
Multilateral organization
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 4150
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3/
            [children] => 
        )

    [access-to-medicines.equitable-access.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 4147
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15/
            [children] => 
        )

    [access-to-medicines.outbreak-preparedness.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 102
            [slug] => outbreak-preparedness
            [title] => Preparedness & response
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Preparedness & response
            [provision_id] => 5808
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-16/
            [children] => 
        )

    [access-to-medicines.pricing.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 4149
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 4148
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13/
            [children] => 
        )

    [business-model.regulatory-strategy.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 4161
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14/
            [children] => 
        )

    [business-model.roles-responsibilities.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4159
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12/
            [children] => 
        )

    [business-model.royalties-and-payments.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 4149
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2/
            [children] => 
        )

    [business-model.supply-purchase-of-products.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 4148
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13/
            [children] => 
        )

    [information-sharing.confidentiality.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4151
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4152
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5/
            [children] => 
        )

    [ip-ownership.license-grants.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 4146
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement/
            [children] => 
        )

    [ip-ownership.ownership-ip.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 4146
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement/
            [children] => 
        )

    [liability.indemnity.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 4153
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6/
            [children] => 
        )

    [liability.insurance.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 4154
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7/
            [children] => 
        )

    [liability.warranties.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4155
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8/
            [children] => 
        )

    [term-and-termination.effect-of-termination.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4158
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11/
            [children] => 
        )

    [term-and-termination.term-of-agreement.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 4156
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 4157
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10/
            [children] => 
        )

)
Gilead - Indian Generic Manufacturers, HCV License Agreement
2014
Industry
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [business-model.royalties-and-payments.gilead-indian-generic-manufacturers-hcv-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3691
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-indian-generic-manufacturers-hcv-license-agreement-2/
            [children] => 
        )

    [information-sharing.technology-transfer.gilead-indian-generic-manufacturers-hcv-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 3694
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-indian-generic-manufacturers-hcv-license-agreement-4/
            [children] => 
        )

    [ip-ownership.license-grants.gilead-hcv-license-agreement-with-indian-generic-manufacturers-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 1145
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-hcv-license-agreement-with-indian-generic-manufacturers-2/
            [children] => 
        )

    [ip-ownership.ownership-ip.gilead-hcv-license-agreement-with-indian-generic-manufacturers-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 1145
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-hcv-license-agreement-with-indian-generic-manufacturers-2/
            [children] => 
        )

    [ip-ownership.protection-results.gilead-hcv-license-agreement-with-indian-generic-manufacturers-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 1145
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-hcv-license-agreement-with-indian-generic-manufacturers-2/
            [children] => 
        )

    [liability.indemnity.gilead-indian-generic-manufacturers-hcv-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3689
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-indian-generic-manufacturers-hcv-license-agreement/
            [children] => 
        )

    [liability.insurance.gilead-hcv-license-agreement-with-indian-generic-manufacturers-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 1264
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-hcv-license-agreement-with-indian-generic-manufacturers-3/
            [children] => 
        )

)
Gilead - MPP - Arene Lifesciences, HIV Therapeutic License Agreement
2018
Industry
Multilateral organization
Drug
Commercialization
Array
(
    [access-to-medicines.territory-access-commitments.gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 5800
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-3/
            [children] => 
        )

    [business-model.regulatory-strategy.gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 5800
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-3/
            [children] => 
        )

    [business-model.roles-responsibilities.gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 5806
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-8/
            [children] => 
        )

    [business-model.royalties-and-payments.gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 5798
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement/
            [children] => 
        )

    [information-sharing.confidentiality.mpp-license-agreement-with-gilead-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 1249
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.gilead-mpp-tdf-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 5790
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-mpp-tdf-license-agreement/
            [children] => 
        )

    [information-sharing.technology-transfer.mpp-license-agreement-with-gilead-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 1228
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-3/
            [children] => 
        )

    [ip-ownership.license-grants.mpp-license-agreement-with-gilead] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 1114
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead/
            [children] => 
        )

    [ip-ownership.protection-results.gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 5799
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-2/
            [children] => 
        )

    [liability.indemnity.mpp-license-agreement-with-gilead-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1263
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-5/
            [children] => 
        )

    [liability.insurance.gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 5803
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-5/
            [children] => 
        )

    [liability.warranties.gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 5802
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-4/
            [children] => 
        )

    [term-and-termination.effect-of-termination.gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 5805
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-7/
            [children] => 
        )

    [term-and-termination.term-of-agreement.gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 5804
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-6/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 5805
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-7/
            [children] => 
        )

)
IMI 1 Model Grant Agreement
2011
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [ip-ownership.license-grants.imi-1-model-grant-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 1171
            [provision_permalink] => https://ghiaa.org/provision_document/imi-1-model-grant-agreement-3/
            [children] => 
        )

    [ip-ownership.ownership-ip.imi-1-model-grant-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 1111
            [provision_permalink] => https://ghiaa.org/provision_document/imi-1-model-grant-agreement/
            [children] => 
        )

)
IMI 2 JU Model Consortium Agreement
2017
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [information-sharing.confidentiality.imi-2-joint-undertaking-model-consortium-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 1245
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-5/
            [children] => 
        )

    [information-sharing.technology-transfer.imi-2-joint-undertaking-model-consortium-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 1237
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-4/
            [children] => 
        )

    [ip-ownership.license-grants.imi-2joint-undertaking-model-consortium-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 1309
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2joint-undertaking-model-consortium-agreement/
            [children] => 
        )

    [ip-ownership.ownership-ip.imi-2joint-undertaking-model-consortium-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 1309
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2joint-undertaking-model-consortium-agreement/
            [children] => 
        )

    [ip-ownership.protection-results.imi-2-joint-undertaking-model-consortium-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 1166
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-2/
            [children] => 
        )

    [liability.indemnity.imi-2-joint-undertaking-model-consortium-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1266
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-8/
            [children] => 
        )

)
IMI 2 Model Grant Agreement
2017
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [access-to-medicines.ensuring-continuity.imi-2-model-grant-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 1178
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-5/
            [children] => 
        )

    [information-sharing.confidentiality.imi-2-model-grant-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 1253
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-8/
            [children] => 
        )

    [information-sharing.publication-of-results.imi-2-model-grant-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 1211
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-6/
            [children] => 
        )

    [ip-ownership.license-grants.imi-2-model-grant-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 1128
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement/
            [children] => 
        )

    [ip-ownership.ownership-ip.imi-2-model-grant-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 1308
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-12/
            [children] => 
        )

    [ip-ownership.protection-results.imi-2-model-grant-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 1165
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-3/
            [children] => 
        )

    [liability.indemnity.imi-2-model-grant-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1268
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-9/
            [children] => 
        )

)
India Department of Biotechnology (DBT), Memorandum of Agreement
2023
Academic institution
Government
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Array
(
    [access-to-medicines.ensuring-continuity.india-department-of-biotechnology-dbt-memorandum-of-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 11696
            [provision_permalink] => https://ghiaa.org/provision_document/india-department-of-biotechnology-dbt-memorandum-of-agreement-2/
            [children] => 
        )

    [access-to-medicines.equitable-access.india-department-of-biotechnology-dbt-memorandum-of-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 11696
            [provision_permalink] => https://ghiaa.org/provision_document/india-department-of-biotechnology-dbt-memorandum-of-agreement-2/
            [children] => 
        )

    [business-model.roles-responsibilities.india-department-of-biotechnology-dbt-memorandum-of-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 11701
            [provision_permalink] => https://ghiaa.org/provision_document/india-department-of-biotechnology-dbt-memorandum-of-agreement-6/
            [children] => 
        )

    [business-model.royalties-and-payments.india-department-of-biotechnology-dbt-memorandum-of-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 11700
            [provision_permalink] => https://ghiaa.org/provision_document/india-department-of-biotechnology-dbt-memorandum-of-agreement-5/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.india-department-of-biotechnology-dbt-memorandum-of-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 11699
            [provision_permalink] => https://ghiaa.org/provision_document/india-department-of-biotechnology-dbt-memorandum-of-agreement-4/
            [children] => 
        )

    [information-sharing.publication-of-results.india-department-of-biotechnology-dbt-memorandum-of-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 11698
            [provision_permalink] => https://ghiaa.org/provision_document/india-department-of-biotechnology-dbt-memorandum-of-agreement-3/
            [children] => 
        )

    [ip-ownership.ownership-ip.india-department-of-biotechnology-dbt-memorandum-of-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 11694
            [provision_permalink] => https://ghiaa.org/provision_document/india-department-of-biotechnology-dbt-memorandum-of-agreement/
            [children] => 
        )

    [ip-ownership.protection-results.india-department-of-biotechnology-dbt-memorandum-of-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 11694
            [provision_permalink] => https://ghiaa.org/provision_document/india-department-of-biotechnology-dbt-memorandum-of-agreement/
            [children] => 
        )

    [term-and-termination.effect-of-termination.india-department-of-biotechnology-dbt-memorandum-of-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 11703
            [provision_permalink] => https://ghiaa.org/provision_document/india-department-of-biotechnology-dbt-memorandum-of-agreement-8/
            [children] => 
        )

    [term-and-termination.term-of-agreement.india-department-of-biotechnology-dbt-memorandum-of-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 11702
            [provision_permalink] => https://ghiaa.org/provision_document/india-department-of-biotechnology-dbt-memorandum-of-agreement-7/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.india-department-of-biotechnology-dbt-memorandum-of-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 11703
            [provision_permalink] => https://ghiaa.org/provision_document/india-department-of-biotechnology-dbt-memorandum-of-agreement-8/
            [children] => 
        )

)
Israel - Pfizer, Epidemiological Evidence Collaboration Agreement
2021
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [business-model.roles-responsibilities.2867] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 2867
            [provision_permalink] => https://ghiaa.org/provision_document/2867/
            [children] => 
        )

    [business-model.royalties-and-payments.2867] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 2867
            [provision_permalink] => https://ghiaa.org/provision_document/2867/
            [children] => 
        )

    [information-sharing.confidentiality.israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 2869
            [provision_permalink] => https://ghiaa.org/provision_document/israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-3/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.2867] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 2867
            [provision_permalink] => https://ghiaa.org/provision_document/2867/
            [children] => 
        )

    [information-sharing.publication-of-results.israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 2873
            [provision_permalink] => https://ghiaa.org/provision_document/israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-6/
            [children] => 
        )

    [ip-ownership.ownership-ip.israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 2872
            [provision_permalink] => https://ghiaa.org/provision_document/israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5/
            [children] => 
        )

    [liability.warranties.israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 2870
            [provision_permalink] => https://ghiaa.org/provision_document/israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-4/
            [children] => 
        )

)
Lambert Toolkit, Consortium Agreement D Template
2019
Academic institution
Industry
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [information-sharing.confidentiality.lambert-agreement-d-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 1239
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-5/
            [children] => 
        )

    [information-sharing.publication-of-results.lambert-agreement-d-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 1214
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-14/
            [children] => 
        )

    [ip-ownership.license-grants.lambert-agreement-d-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 1177
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-3/
            [children] => 
        )

    [ip-ownership.ownership-ip.lambert-agreement-d] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 1107
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d/
            [children] => 
        )

    [liability.indemnity.lambert-agreement-d-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1262
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-10/
            [children] => 
        )

    [liability.warranties.lambert-agreement-d-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 1258
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-8/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.lambert-agreement-d-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 1281
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-12/
            [children] => 
        )

)
Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
2023
Industry
Multilateral organization
Vaccine
Commercialization
Array
(
    [access-to-medicines.pricing.mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 11348
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-4/
            [children] => 
        )

    [business-model.regulatory-strategy.mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 11356
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-10/
            [children] => 
        )

    [business-model.roles-responsibilities.mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 11354
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-9/
            [children] => 
        )

    [business-model.royalties-and-payments.mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 11353
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement/
            [children] => 
        )

    [information-sharing.confidentiality.mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 11349
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-6/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 11350
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-7/
            [children] => 
        )

    [information-sharing.technology-transfer.mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 11351
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-8/
            [children] => 
        )

    [ip-ownership.license-grants.mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 11346
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-3/
            [children] => 
        )

    [ip-ownership.ownership-ip.mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 11345
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-2/
            [children] => 
        )

    [ip-ownership.protection-results.mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 11347
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-5/
            [children] => 
        )

    [liability.indemnity.mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 11357
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-11/
            [children] => 
        )

    [liability.insurance.mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 11358
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-12/
            [children] => 
        )

    [liability.warranties.mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 11359
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-13/
            [children] => 
        )

    [term-and-termination.effect-of-termination.mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 11361
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-15/
            [children] => 
        )

    [term-and-termination.term-of-agreement.mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 11360
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-14/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 11361
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-15/
            [children] => 
        )

)
Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
2014
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [information-sharing.confidentiality.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 1242
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-6/
            [children] => 
        )

    [information-sharing.technology-transfer.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 1235
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-4/
            [children] => 
        )

    [ip-ownership.license-grants.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 1140
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-2/
            [children] => 
        )

    [ip-ownership.ownership-ip.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 1112
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation/
            [children] => 
        )

    [liability.indemnity.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1267
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-7/
            [children] => 
        )

    [term-and-termination.effect-of-termination.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 1287
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-10/
            [children] => 
        )

    [term-and-termination.term-of-agreement.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 1285
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 1285
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9/
            [children] => 
        )

)
Merck - MPP, Molnupiravir License Agreement
2021
Industry
Multilateral organization
Drug
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.pricing.msd-mpp-molnupiravir-license-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 3899
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-8/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.msd-mpp-molnupiravir-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 3895
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-4/
            [children] => 
        )

    [business-model.regulatory-strategy.msd-mpp-molnupiravir-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 3910
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement/
            [children] => 
        )

    [business-model.roles-responsibilities.msd-mpp-molnupiravir-license-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 3909
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-17/
            [children] => 
        )

    [business-model.royalties-and-payments.msd-mpp-molnupiravir-license-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3899
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-8/
            [children] => 
        )

    [business-model.supply-purchase-of-products.msd-mpp-molnupiravir-license-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 3898
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-7/
            [children] => 
        )

    [information-sharing.confidentiality.msd-mpp-molnupiravir-license-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3896
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-5/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.msd-mpp-molnupiravir-license-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3908
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-16/
            [children] => 
        )

    [information-sharing.technology-transfer.msd-mpp-molnupiravir-license-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 3897
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-6/
            [children] => 
        )

    [ip-ownership.license-grants.msd-mpp-molnupiravir-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 3892
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-3/
            [children] => 
        )

    [ip-ownership.ownership-ip.msd-mpp-molnupiravir-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 3892
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-3/
            [children] => 
        )

    [ip-ownership.protection-results.msd-mpp-molnupiravir-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 3891
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-2/
            [children] => 
        )

    [liability.indemnity.msd-mpp-molnupiravir-license-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3900
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-9/
            [children] => 
        )

    [liability.insurance.msd-mpp-molnupiravir-license-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 3901
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-10/
            [children] => 
        )

    [liability.warranties.msd-mpp-molnupiravir-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3903
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-12/
            [children] => 
        )

    [term-and-termination.effect-of-termination.msd-mpp-molnupiravir-license-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 3907
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-15/
            [children] => 
        )

    [term-and-termination.term-of-agreement.msd-mpp-molnupiravir-license-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3904
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-13/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.msd-mpp-molnupiravir-license-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 3906
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-14/
            [children] => 
        )

)
Merck - MPP, Raltegravir License Agreement
2015
Industry
Multilateral organization
Drug
Commercialization
  • No Issues
Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
2020
Industry
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [business-model.regulatory-strategy.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 3886
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-16/
            [children] => 
        )

    [business-model.roles-responsibilities.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 3884
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-14/
            [children] => 
        )

    [business-model.royalties-and-payments.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3876
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-6/
            [children] => 
        )

    [business-model.supply-purchase-of-products.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 3875
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-5/
            [children] => 
        )

    [information-sharing.confidentiality.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3873
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-4/
            [children] => 
        )

    [information-sharing.technology-transfer.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 3874
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-2/
            [children] => 
        )

    [ip-ownership.license-grants.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 3869
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17/
            [children] => 
        )

    [ip-ownership.ownership-ip.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 3869
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17/
            [children] => 
        )

    [ip-ownership.protection-results.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 3870
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement/
            [children] => 
        )

    [liability.indemnity.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3877
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-7/
            [children] => 
        )

    [liability.insurance.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 3878
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-8/
            [children] => 
        )

    [liability.warranties.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3880
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-10/
            [children] => 
        )

    [term-and-termination.effect-of-termination.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 3883
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-13/
            [children] => 
        )

    [term-and-termination.term-of-agreement.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3881
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-11/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 3882
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-12/
            [children] => 
        )

)
MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
2022
Industry
Multilateral organization
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 9062
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2/
            [children] => 
        )

    [business-model.roles-responsibilities.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 9068
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8/
            [children] => 
        )

    [business-model.royalties-and-payments.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 9067
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-7/
            [children] => 
        )

    [information-sharing.confidentiality.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 9064
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 9066
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-6/
            [children] => 
        )

    [information-sharing.publication-of-results.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 9065
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-5/
            [children] => 
        )

    [ip-ownership.license-grants.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 9062
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2/
            [children] => 
        )

    [ip-ownership.ownership-ip.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 9061
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement/
            [children] => 
        )

    [ip-ownership.protection-results.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 9063
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-3/
            [children] => 
        )

    [liability.indemnity.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 9069
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-9/
            [children] => 
        )

    [liability.insurance.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 9070
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-10/
            [children] => 
        )

    [liability.warranties.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 9071
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-11/
            [children] => 
        )

    [term-and-termination.effect-of-termination.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 9073
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13/
            [children] => 
        )

    [term-and-termination.term-of-agreement.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 9072
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-12/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 9073
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13/
            [children] => 
        )

)
MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
2022
Industry
Multilateral organization
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 9077
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2/
            [children] => 
        )

    [business-model.roles-responsibilities.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 9083
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8/
            [children] => 
        )

    [business-model.royalties-and-payments.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 9082
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-7/
            [children] => 
        )

    [information-sharing.confidentiality.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 9079
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 9081
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-6/
            [children] => 
        )

    [information-sharing.publication-of-results.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 9080
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-5/
            [children] => 
        )

    [ip-ownership.license-grants.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 9077
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2/
            [children] => 
        )

    [ip-ownership.ownership-ip.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 9076
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement/
            [children] => 
        )

    [ip-ownership.protection-results.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 9078
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-3/
            [children] => 
        )

    [liability.indemnity.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 9086
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-9/
            [children] => 
        )

    [liability.insurance.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 9087
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-10/
            [children] => 
        )

    [liability.warranties.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 9088
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-11/
            [children] => 
        )

    [term-and-termination.effect-of-termination.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 9090
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13/
            [children] => 
        )

    [term-and-termination.term-of-agreement.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 9089
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-12/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 9090
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13/
            [children] => 
        )

)
MPP (C-TAP) - Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
2022
Industry
Multilateral organization
Diagnostic
Commercialization
Array
(
    [access-to-medicines.equitable-access.mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 11605
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-10/
            [children] => 
        )

    [access-to-medicines.pricing.mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 11606
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-11/
            [children] => 
        )

    [business-model.roles-responsibilities.mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 11613
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-7/
            [children] => 
        )

    [business-model.royalties-and-payments.mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 11611
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-6/
            [children] => 
        )

    [information-sharing.confidentiality.mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 11607
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 11609
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-12/
            [children] => 
        )

    [information-sharing.technology-transfer.mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 11610
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-13/
            [children] => 
        )

    [ip-ownership.license-grants.mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 11602
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-5/
            [children] => 
        )

    [ip-ownership.protection-results.mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 11604
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-9/
            [children] => 
        )

    [liability.indemnity.mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 11614
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-2/
            [children] => 
        )

    [liability.insurance.mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 11616
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-3/
            [children] => 
        )

    [liability.warranties.mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 11617
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-4/
            [children] => 
        )

    [term-and-termination.effect-of-termination.mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 11618
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-8/
            [children] => 
        )

    [term-and-termination.term-of-agreement.mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 11618
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-8/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 11618
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-8/
            [children] => 
        )

)
National Health Service (NHS) – Pfizer/Shionogi, Antibiotic Supply Agreement
2022
Government
Industry
Drug
Commercialization
Array
(
    [business-model.regulatory-strategy.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 9022
            [provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-7/
            [children] => 
        )

    [business-model.roles-responsibilities.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 9021
            [provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-6/
            [children] => 
        )

    [business-model.royalties-and-payments.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 9016
            [provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-5/
            [children] => 
        )

    [business-model.supply-purchase-of-products.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 9015
            [provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-4/
            [children] => 
        )

    [information-sharing.confidentiality.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 9013
            [provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-2/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 9014
            [provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-3/
            [children] => 
        )

    [ip-ownership.license-grants.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 9012
            [provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement/
            [children] => 
        )

    [liability.indemnity.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 9023
            [provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-8/
            [children] => 
        )

    [liability.insurance.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 9024
            [provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-9/
            [children] => 
        )

    [liability.warranties.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 9025
            [provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-10/
            [children] => 
        )

    [term-and-termination.effect-of-termination.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 9028
            [provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-13/
            [children] => 
        )

    [term-and-termination.term-of-agreement.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 9026
            [provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-11/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 9027
            [provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-12/
            [children] => 
        )

)
NIAID - AbCellera, COVID-19 Exclusive Patent License Agreement
2020
Government
Industry
Vaccine
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.niaid-abcellera-covid-19-exclusive-patent-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 11741
            [provision_permalink] => https://ghiaa.org/provision_document/niaid-abcellera-covid-19-exclusive-patent-license-agreement-3/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.niaid-abcellera-covid-19-exclusive-patent-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 11742
            [provision_permalink] => https://ghiaa.org/provision_document/niaid-abcellera-covid-19-exclusive-patent-license-agreement-4/
            [children] => 
        )

    [business-model.royalties-and-payments.niaid-abcellera-covid-19-exclusive-patent-license-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 11746
            [provision_permalink] => https://ghiaa.org/provision_document/niaid-abcellera-covid-19-exclusive-patent-license-agreement-8/
            [children] => 
        )

    [information-sharing.confidentiality.niaid-abcellera-covid-19-exclusive-patent-license-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 11743
            [provision_permalink] => https://ghiaa.org/provision_document/niaid-abcellera-covid-19-exclusive-patent-license-agreement-5/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.niaid-abcellera-covid-19-exclusive-patent-license-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 11745
            [provision_permalink] => https://ghiaa.org/provision_document/niaid-abcellera-covid-19-exclusive-patent-license-agreement-7/
            [children] => 
        )

    [information-sharing.publication-of-results.niaid-abcellera-covid-19-exclusive-patent-license-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 11744
            [provision_permalink] => https://ghiaa.org/provision_document/niaid-abcellera-covid-19-exclusive-patent-license-agreement-6/
            [children] => 
        )

    [ip-ownership.license-grants.niaid-abcellera-covid-19-exclusive-patent-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 11724
            [provision_permalink] => https://ghiaa.org/provision_document/niaid-abcellera-covid-19-exclusive-patent-license-agreement/
            [children] => 
        )

    [ip-ownership.protection-results.niaid-abcellera-covid-19-exclusive-patent-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 11740
            [provision_permalink] => https://ghiaa.org/provision_document/niaid-abcellera-covid-19-exclusive-patent-license-agreement-2/
            [children] => 
        )

    [liability.indemnity.niaid-abcellera-covid-19-exclusive-patent-license-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 11747
            [provision_permalink] => https://ghiaa.org/provision_document/niaid-abcellera-covid-19-exclusive-patent-license-agreement-9/
            [children] => 
        )

    [liability.insurance.niaid-abcellera-covid-19-exclusive-patent-license-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 11748
            [provision_permalink] => https://ghiaa.org/provision_document/niaid-abcellera-covid-19-exclusive-patent-license-agreement-10/
            [children] => 
        )

    [liability.warranties.niaid-abcellera-covid-19-exclusive-patent-license-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 11749
            [provision_permalink] => https://ghiaa.org/provision_document/niaid-abcellera-covid-19-exclusive-patent-license-agreement-11/
            [children] => 
        )

    [term-and-termination.effect-of-termination.niaid-abcellera-covid-19-exclusive-patent-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 11750
            [provision_permalink] => https://ghiaa.org/provision_document/niaid-abcellera-covid-19-exclusive-patent-license-agreement-12/
            [children] => 
        )

    [term-and-termination.term-of-agreement.niaid-abcellera-covid-19-exclusive-patent-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 11750
            [provision_permalink] => https://ghiaa.org/provision_document/niaid-abcellera-covid-19-exclusive-patent-license-agreement-12/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.niaid-abcellera-covid-19-exclusive-patent-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 11750
            [provision_permalink] => https://ghiaa.org/provision_document/niaid-abcellera-covid-19-exclusive-patent-license-agreement-12/
            [children] => 
        )

)
NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
2020
Government
Industry
Diagnostic
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.nih-fluidigm-covid-19-diagnostic-development-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 11031
            [provision_permalink] => https://ghiaa.org/provision_document/nih-fluidigm-covid-19-diagnostic-development-agreement-6/
            [children] => 
        )

    [access-to-medicines.pricing.nih-fluidigm-covid-19-diagnostic-development-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 11021
            [provision_permalink] => https://ghiaa.org/provision_document/nih-fluidigm-covid-19-diagnostic-development-agreement-11/
            [children] => 
        )

    [business-model.regulatory-strategy.nih-fluidigm-covid-19-diagnostic-development-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 11019
            [provision_permalink] => https://ghiaa.org/provision_document/nih-fluidigm-covid-19-diagnostic-development-agreement-12/
            [children] => 
        )

    [business-model.roles-responsibilities.nih-fluidigm-covid-19-diagnostic-development-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 11023
            [provision_permalink] => https://ghiaa.org/provision_document/nih-fluidigm-covid-19-diagnostic-development-agreement-10/
            [children] => 
        )

    [business-model.royalties-and-payments.nih-fluidigm-covid-19-diagnostic-development-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 11032
            [provision_permalink] => https://ghiaa.org/provision_document/nih-fluidigm-covid-19-diagnostic-development-agreement-4/
            [children] => 
        )

    [business-model.supply-purchase-of-products.nih-fluidigm-covid-19-diagnostic-development-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 11018
            [provision_permalink] => https://ghiaa.org/provision_document/nih-fluidigm-covid-19-diagnostic-development-agreement-7/
            [children] => 
        )

    [information-sharing.confidentiality.nih-fluidigm-covid-19-diagnostic-development-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 11026
            [provision_permalink] => https://ghiaa.org/provision_document/nih-fluidigm-covid-19-diagnostic-development-agreement-3/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.nih-fluidigm-covid-19-diagnostic-development-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 11020
            [provision_permalink] => https://ghiaa.org/provision_document/nih-fluidigm-covid-19-diagnostic-development-agreement-5/
            [children] => 
        )

    [information-sharing.publication-of-results.nih-fluidigm-covid-19-diagnostic-development-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 11030
            [provision_permalink] => https://ghiaa.org/provision_document/nih-fluidigm-covid-19-diagnostic-development-agreement-2/
            [children] => 
        )

    [ip-ownership.license-grants.nih-fluidigm-covid-19-diagnostic-development-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 11028
            [provision_permalink] => https://ghiaa.org/provision_document/nih-fluidigm-covid-19-diagnostic-development-agreement-9/
            [children] => 
        )

    [ip-ownership.ownership-ip.nih-fluidigm-covid-19-diagnostic-development-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 11028
            [provision_permalink] => https://ghiaa.org/provision_document/nih-fluidigm-covid-19-diagnostic-development-agreement-9/
            [children] => 
        )

    [ip-ownership.protection-results.nih-fluidigm-covid-19-diagnostic-development-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 11028
            [provision_permalink] => https://ghiaa.org/provision_document/nih-fluidigm-covid-19-diagnostic-development-agreement-9/
            [children] => 
        )

    [liability.indemnity.nih-fluidigm-covid-19-diagnostic-development-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 11029
            [provision_permalink] => https://ghiaa.org/provision_document/nih-fluidigm-covid-19-diagnostic-development-agreement-8/
            [children] => 
        )

    [term-and-termination.effect-of-termination.nih-fluidigm-covid-19-diagnostic-development-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 11022
            [provision_permalink] => https://ghiaa.org/provision_document/nih-fluidigm-covid-19-diagnostic-development-agreement/
            [children] => 
        )

    [term-and-termination.term-of-agreement.nih-fluidigm-covid-19-diagnostic-development-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 11022
            [provision_permalink] => https://ghiaa.org/provision_document/nih-fluidigm-covid-19-diagnostic-development-agreement/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.nih-fluidigm-covid-19-diagnostic-development-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 11022
            [provision_permalink] => https://ghiaa.org/provision_document/nih-fluidigm-covid-19-diagnostic-development-agreement/
            [children] => 
        )

)
NIH - GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
2020
Government
Industry
Vaccine
Preclinical
Commercialization
Array
(
    [access-to-medicines.territory-access-commitments.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 3414
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-8/
            [children] => 
        )

    [business-model.roles-responsibilities.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 3418
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-12/
            [children] => 
        )

    [business-model.royalties-and-payments.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3410
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-4/
            [children] => 
        )

    [business-model.supply-purchase-of-products.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 11083
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-3/
            [children] => 
        )

    [information-sharing.confidentiality.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3413
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-7/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3412
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-6/
            [children] => 
        )

    [information-sharing.publication-of-results.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 3412
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-6/
            [children] => 
        )

    [ip-ownership.license-grants.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 3406
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement/
            [children] => 
        )

    [ip-ownership.protection-results.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 3411
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-5/
            [children] => 
        )

    [liability.indemnity.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3415
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-9/
            [children] => 
        )

    [liability.insurance.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 11000
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-2/
            [children] => 
        )

    [liability.warranties.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3415
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-9/
            [children] => 
        )

    [term-and-termination.effect-of-termination.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 3416
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-10/
            [children] => 
        )

    [term-and-termination.term-of-agreement.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3416
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-10/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 3416
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-10/
            [children] => 
        )

)
NIH - Non-Profit, Model License Agreement Terms
2017
Government
Multilateral organization
Product development partnership
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [access-to-medicines.ensuring-continuity.nih-non-profit-model-license-agreement-terms] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 10999
            [provision_permalink] => https://ghiaa.org/provision_document/nih-non-profit-model-license-agreement-terms/
            [children] => 
        )

    [access-to-medicines.equitable-access.nih-non-profit-model-license-agreement-terms-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 11004
            [provision_permalink] => https://ghiaa.org/provision_document/nih-non-profit-model-license-agreement-terms-2/
            [children] => 
        )

    [business-model.royalties-and-payments.nih-non-profit-model-license-agreement-terms-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 11005
            [provision_permalink] => https://ghiaa.org/provision_document/nih-non-profit-model-license-agreement-terms-3/
            [children] => 
        )

    [ip-ownership.license-grants.nih-model-license-agreement-for-use-by-non-profit] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 1135
            [provision_permalink] => https://ghiaa.org/provision_document/nih-model-license-agreement-for-use-by-non-profit/
            [children] => 
        )

    [ip-ownership.protection-results.nih-model-license-agreement-for-use-by-non-profit-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 1168
            [provision_permalink] => https://ghiaa.org/provision_document/nih-model-license-agreement-for-use-by-non-profit-2/
            [children] => 
        )

    [term-and-termination.term-of-agreement.11002] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 11002
            [provision_permalink] => https://ghiaa.org/provision_document/11002/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.nih-non-profit-model-license-agreement-terms] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 10999
            [provision_permalink] => https://ghiaa.org/provision_document/nih-non-profit-model-license-agreement-terms/
            [children] => 
        )

)
NIH - UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
2011
Government
Industry
Drug
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 11126
            [provision_permalink] => https://ghiaa.org/provision_document/nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-4/
            [children] => 
        )

    [access-to-medicines.pricing.nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 11096
            [provision_permalink] => https://ghiaa.org/provision_document/nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 11129
            [provision_permalink] => https://ghiaa.org/provision_document/nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-7/
            [children] => 
        )

    [business-model.roles-responsibilities.nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 11134
            [provision_permalink] => https://ghiaa.org/provision_document/nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-12/
            [children] => 
        )

    [business-model.royalties-and-payments.nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 11096
            [provision_permalink] => https://ghiaa.org/provision_document/nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement/
            [children] => 
        )

    [information-sharing.confidentiality.nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 11127
            [provision_permalink] => https://ghiaa.org/provision_document/nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-5/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 11128
            [provision_permalink] => https://ghiaa.org/provision_document/nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-6/
            [children] => 
        )

    [information-sharing.publication-of-results.nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 11128
            [provision_permalink] => https://ghiaa.org/provision_document/nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-6/
            [children] => 
        )

    [ip-ownership.license-grants.nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 11125
            [provision_permalink] => https://ghiaa.org/provision_document/nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-3/
            [children] => 
        )

    [ip-ownership.protection-results.nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 11097
            [provision_permalink] => https://ghiaa.org/provision_document/nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-2/
            [children] => 
        )

    [liability.indemnity.nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 11131
            [provision_permalink] => https://ghiaa.org/provision_document/nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-9/
            [children] => 
        )

    [liability.insurance.nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 11132
            [provision_permalink] => https://ghiaa.org/provision_document/nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-10/
            [children] => 
        )

    [liability.warranties.nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 11130
            [provision_permalink] => https://ghiaa.org/provision_document/nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-8/
            [children] => 
        )

    [term-and-termination.effect-of-termination.nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 11133
            [provision_permalink] => https://ghiaa.org/provision_document/nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-11/
            [children] => 
        )

    [term-and-termination.term-of-agreement.nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 11133
            [provision_permalink] => https://ghiaa.org/provision_document/nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-11/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 11133
            [provision_permalink] => https://ghiaa.org/provision_document/nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-11/
            [children] => 
        )

)
NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
2022
Government
Multilateral organization
Diagnostic
Drug
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.equitable-access.nih-mpp-covid-19-patent-and-biological-material-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 5114
            [provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-4/
            [children] => 
        )

    [access-to-medicines.pricing.nih-mpp-covid-19-patent-and-biological-material-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 5113
            [provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-3/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.nih-mpp-covid-19-patent-and-biological-material-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 5123
            [provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-12/
            [children] => 
        )

    [business-model.roles-responsibilities.5122] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 5122
            [provision_permalink] => https://ghiaa.org/provision_document/5122/
            [children] => 
        )

    [business-model.royalties-and-payments.nih-mpp-covid-19-patent-and-biological-material-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 5113
            [provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-3/
            [children] => 
        )

    [business-model.supply-purchase-of-products.nih-mpp-covid-19-patent-and-biological-material-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 5123
            [provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-12/
            [children] => 
        )

    [information-sharing.confidentiality.nih-mpp-covid-19-patent-and-biological-material-license-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 5115
            [provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-5/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.nih-mpp-covid-19-patent-and-biological-material-license-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 5121
            [provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-11/
            [children] => 
        )

    [information-sharing.publication-of-results.nih-mpp-covid-19-patent-and-biological-material-license-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 5121
            [provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-11/
            [children] => 
        )

    [ip-ownership.license-grants.nih-mpp-covid-19-patent-and-biological-material-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 5111
            [provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement/
            [children] => 
        )

    [ip-ownership.ownership-ip.nih-mpp-covid-19-patent-and-biological-material-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 5111
            [provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement/
            [children] => 
        )

    [ip-ownership.protection-results.nih-mpp-covid-19-patent-and-biological-material-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 5112
            [provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-2/
            [children] => 
        )

    [liability.indemnity.nih-mpp-covid-19-patent-and-biological-material-license-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 5116
            [provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-6/
            [children] => 
        )

    [liability.insurance.nih-mpp-covid-19-patent-and-biological-material-license-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 5117
            [provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-7/
            [children] => 
        )

    [liability.warranties.nih-mpp-covid-19-patent-and-biological-material-license-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 5118
            [provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-8/
            [children] => 
        )

    [term-and-termination.effect-of-termination.nih-mpp-covid-19-patent-and-biological-material-license-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 5120
            [provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-10/
            [children] => 
        )

    [term-and-termination.term-of-agreement.nih-mpp-covid-19-patent-and-biological-material-license-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 5119
            [provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-9/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.nih-mpp-covid-19-patent-and-biological-material-license-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 5120
            [provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-10/
            [children] => 
        )

)
Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
2020
Industry
Vaccine
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 3808
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 3806
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11/
            [children] => 
        )

    [business-model.regulatory-strategy.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 3807
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12/
            [children] => 
        )

    [business-model.roles-responsibilities.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 3810
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15/
            [children] => 
        )

    [business-model.royalties-and-payments.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3801
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6/
            [children] => 
        )

    [business-model.supply-purchase-of-products.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 3809
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14/
            [children] => 
        )

    [information-sharing.confidentiality.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3799
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4661
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16/
            [children] => 
        )

    [information-sharing.technology-transfer.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 3800
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-5/
            [children] => 
        )

    [ip-ownership.license-grants.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 3796
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement/
            [children] => 
        )

    [ip-ownership.ownership-ip.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 3797
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2/
            [children] => 
        )

    [ip-ownership.protection-results.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 3798
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3/
            [children] => 
        )

    [liability.indemnity.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3802
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7/
            [children] => 
        )

    [liability.insurance.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 3803
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8/
            [children] => 
        )

    [liability.warranties.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3812
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17/
            [children] => 
        )

    [term-and-termination.effect-of-termination.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 3805
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10/
            [children] => 
        )

    [term-and-termination.term-of-agreement.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3804
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 3804
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9/
            [children] => 
        )

)
Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
    [business-model.regulatory-strategy.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-20] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 4054
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-20/
            [children] => 
        )

    [business-model.roles-responsibilities.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4051
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-17/
            [children] => 
        )

    [business-model.royalties-and-payments.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 4040
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-8/
            [children] => 
        )

    [business-model.supply-purchase-of-products.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 4041
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-9/
            [children] => 
        )

    [information-sharing.confidentiality.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4032
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-3/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4036
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-5/
            [children] => 
        )

    [information-sharing.publication-of-results.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 4035
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-4/
            [children] => 
        )

    [information-sharing.technology-transfer.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 4038
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-7/
            [children] => 
        )

    [ip-ownership.license-grants.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 4029
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-2/
            [children] => 
        )

    [ip-ownership.ownership-ip.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 4028
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement/
            [children] => 
        )

    [liability.indemnity.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 4042
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-10/
            [children] => 
        )

    [liability.insurance.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 4043
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-11/
            [children] => 
        )

    [liability.warranties.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4045
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-13/
            [children] => 
        )

    [term-and-termination.effect-of-termination.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4050
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-16/
            [children] => 
        )

    [term-and-termination.term-of-agreement.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 4046
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-14/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 4047
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-15/
            [children] => 
        )

)
PATH - Aridis, Rotavirus Vaccine Development Agreement
2007
Industry
Product development partnership
Vaccine
Early clinical (through Phase 2)
Array
(
    [access-to-medicines.ensuring-continuity.path-aridis-rotavirus-vaccine-development-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 5809
            [provision_permalink] => https://ghiaa.org/provision_document/path-aridis-rotavirus-vaccine-development-agreement-8/
            [children] => 
        )

    [access-to-medicines.equitable-access.path-aridis-rotavirus-vaccine-development-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 4060
            [provision_permalink] => https://ghiaa.org/provision_document/path-aridis-rotavirus-vaccine-development-agreement/
            [children] => 
        )

    [access-to-medicines.pricing.aridis-path-vaccine-formulation-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 1190
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-2/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.aridis-path-vaccine-formulation-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 1190
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-2/
            [children] => 
        )

    [business-model.roles-responsibilities.path-aridis-rotavirus-vaccine-development-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4061
            [provision_permalink] => https://ghiaa.org/provision_document/path-aridis-rotavirus-vaccine-development-agreement-2/
            [children] => 
        )

    [business-model.royalties-and-payments.path-aridis-rotavirus-vaccine-development-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 4063
            [provision_permalink] => https://ghiaa.org/provision_document/path-aridis-rotavirus-vaccine-development-agreement-4/
            [children] => 
        )

    [information-sharing.confidentiality.aridis-path-vaccine-formulation-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 1240
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.path-aridis-rotavirus-vaccine-development-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4062
            [provision_permalink] => https://ghiaa.org/provision_document/path-aridis-rotavirus-vaccine-development-agreement-3/
            [children] => 
        )

    [information-sharing.publication-of-results.path-aridis-rotavirus-vaccine-development-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 4066
            [provision_permalink] => https://ghiaa.org/provision_document/path-aridis-rotavirus-vaccine-development-agreement-7/
            [children] => 
        )

    [ip-ownership.license-grants.aridis-path-vaccine-formulation-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => license-grants
            [title] => License Grants
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | License Grants
            [provision_id] => 1176
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement/
            [children] => 
        )

    [ip-ownership.ownership-ip.aridis-path-vaccine-formulation-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 1160
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-8/
            [children] => 
        )

    [ip-ownership.protection-results.aridis-path-vaccine-formulation-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 1160
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-8/
            [children] => 
        )

    [liability.indemnity.aridis-path-vaccine-formulation-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1275
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-5/
            [children] => 
        )

    [liability.insurance.path-aridis-rotavirus-vaccine-development-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 4065
            [provision_permalink] => https://ghiaa.org/provision_document/path-aridis-rotavirus-vaccine-development-agreement-6/
            [children] => 
        )

    [liability.warranties.path-aridis-rotavirus-vaccine-development-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4064
            [provision_permalink] => https://ghiaa.org/provision_document/path-aridis-rotavirus-vaccine-development-agreement-5/
            [children] => 
        )

    [term-and-termination.effect-of-termination.aridis-path-vaccine-formulation-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 1283
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-6/
            [children] => 
        )

    [term-and-termination.term-of-agreement.aridis-path-vaccine-formulation-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 1283
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-6/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.aridis-path-vaccine-formulation-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 1283
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-6/
            [children] => 
        )

)
Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
2021
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
    [business-model.roles-responsibilities.pfizer-peru-covid-19-vaccine-binding-term-sheet-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 3220
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-peru-covid-19-vaccine-binding-term-sheet-6/
            [children] => 
        )

    [business-model.supply-purchase-of-products.pfizer-peru-covid-19-vaccine-binding-term-sheet-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 3217
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-peru-covid-19-vaccine-binding-term-sheet-3/
            [children] => 
        )

    [information-sharing.confidentiality.pfizer-peru-covid-19-vaccine-binding-term-sheet-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3218
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-peru-covid-19-vaccine-binding-term-sheet-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.pfizer-peru-covid-19-vaccine-binding-term-sheet-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3221
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-peru-covid-19-vaccine-binding-term-sheet-7/
            [children] => 
        )

    [ip-ownership.ownership-ip.pfizer-peru-covid-19-vaccine-binding-term-sheet] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-ip
            [title] => Ownership of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of IP
            [provision_id] => 3215
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-peru-covid-19-vaccine-binding-term-sheet/
            [children] => 
        )

    [liability.indemnity.pfizer-peru-covid-19-vaccine-binding-term-sheet-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3219
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-peru-covid-19-vaccine-binding-term-sheet-5/
            [children] => 
        )

)
Pfizer - MPP, Sutezolid License Agreement
2019
Industry
Multilateral organization
Drug
Commercialization
Array
(
    [access-to-medicines.pricing.mpp-license-agreement-with-pfizer-re-sutezolid] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 1207
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-pfizer-re-sutezolid/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.mpp-license-agreement-with-pfizer-re-sutezolid] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 1207
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-pfizer-re-sutezolid/
            [children] => 
        )

)
PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
2005
Government
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 11068
            [provision_permalink] => https://ghiaa.org/provision_document/phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-3/
            [children] => 
        )

    [access-to-medicines.equitable-access.phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 11075
            [provision_permalink] => https://ghiaa.org/provision_document/phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-10/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 11074
            [provision_permalink] => https://ghiaa.org/provision_document/phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-9/
            [children] => 
        )

    [business-model.roles-responsibilities.phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 11078
            [provision_permalink] => https://ghiaa.org/provision_document/phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-13/
            [children] => 
        )

    [business-model.royalties-and-payments.phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 11071
            [provision_permalink] => https://ghiaa.org/provision_document/phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-6/
            [children] => 
        )

    [business-model.supply-purchase-of-products.phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 11070
            [provision_permalink] => https://ghiaa.org/provision_document/phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-5/
            [children] => 
        )

    [information-sharing.confidentiality.phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-ag